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ABSTRACT
Deepa Viswanathan (Ajit) . University of Missouri-Saint Louis, September 2009. Role of
Amyloid Beta Assembly State in the Human Immune Response.

Major Professor: Michael R. Nichols
Alzheimer‟s disease (AD) is a slowly progressing neurodegenerative disease that leads to
dementia. Histopathological hallmarks that characterize AD are senile plaques formed by
extracellular deposition of Amyloid beta (Aβ) peptide and intracellular aggregates of
hyperphosphorylated tau protein. The plaques, which are found in the brain parenchyma,
comprise both 40 and 42 residue Aβ. Aggregation of Aβ is an established pathogenic
mechanism in AD, but little is known about the initiation of this process in vivo. Several
studies have revealed significant inflammatory markers such as activated microglia and
cytokines surrounding the plaques. Plaques are a hallmark of AD, but they are only part
of an array of Aβ aggregate morphologies observed in vivo. Structural polymorphism is a
prominent feature of Aβ aggregation both in vitro and in vivo. The molecular relationship
between the different forms of Aβ remains to be determined. Inflammatory processes are
believed to contribute to AD pathophysiology, and may play an important role in the
disease progression. Not all Aβ deposits evoke a proinflammatory response, making it all
the more important to probe into structural details of the Aβ aggregation pathway. This
research was aimed at investigating what Aβ morphology or aggregation species induce
the strongest proinflammatory response in human THP-1 monocytes as a model system.
Our results indicate that an intermediate fibrillar aggregation species formed when Aβ(142) is reconstituted in water (100 M, pH 3.6) and incubated at 4C under quiescent
conditions was capable of stimulating maximum tumor necrosis factor alpha (TNF).
Modulating conditions that accelerated or increased Aβ(1-42) fibril formation such as
temperature, peptide concentration, or pH diminished the ability to activate the cells.
Immunodepletion of Aβ(1-42) solution with fibril specific antibody (OC immune serum)
reduced the ability to induce TNF production. Characterization by SEC showed an
included peak that appeared immediately after the void volume and stimulated the
maximum proinflammatory response. We have also shown that the shorter peptide Aβ(140) could not stimulate a proinflammatory response under similar aggregation conditions.
Overall, the data suggest that an intermediate Aβ(1-42) fibrillar precursor species is
optimal for inducing maximum proinflammatory activity in THP-1 monocytes.
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CHAPTER 1
INTRODUCTION

1.1 Protein Misfolding and Amyloid Formation

Proteins are involved in virtually every biological process in the living system.
The amino acids in the protein must fold into the native three-dimensional structures, and
these structures are characteristic of individual proteins (Voet, 1995). The folding of a
protein is influenced by its amino acid sequence, and the cellular environment around the
amino acid chain (Anfinsen, 1973, Horwich et al., 1999). The folding and unfolding of
proteins is associated with a wide range of cellular processes from the trafficking of
molecules to specific organelles to the regulation of the cell cycle and the immune
response (Radford and Dobson, 1999, Stefani and Dobson, 2003). These observations led
to the conclusion that the failure to fold correctly, or to remain folded correctly, leads to
many different types of biological malfunctions and hence to many different forms of
diseases (Radford and Dobson, 1999). In the case of incompletely folded proteins, some
regions of the structure that are actually buried in the native state will be exposed to the
solvent. Hence, these proteins are prone to inappropriate interaction with other molecules
within the crowded environment of the cell (Ellis, 2001). Therefore living systems have
evolved strategies to prevent unwanted interactions. The cell has evolved the chaperone
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system, and some chaperones interact with the nascent proteins as they emerge out of the
ribosomes, while others are involved in guiding later stages of the folding process (Bukau
and Horwich, 1998, Hartl and Hayer-Hartl, 2002), and hence prevent aggregation.
Furthermore, unfolded proteins that escape the chaperone system are degraded by the
proteasome. However, there is a gradual decrease in the efficiency of the system with
age that could lead to late onset disorders.
Failure of a specific peptide or protein to adopt, or remain in, its native functional
conformational state results in a broad range of human diseases termed as protein folding
disorders (Chiti and Dobson, 2006). Abnormal physiological concentrations and
mutations are believed to destabilize the native three-dimensional state, thereby deviating
the protein from its normal folding pathway (Dobson, 1999, Hetz and Soto, 2003). The
largest group of misfolding diseases is associated with the conversion of specific peptides
or proteins from their soluble functional states ultimately into highly organized fibrillar
aggregates (Lansbury, 1999). The fact that only select groups of proteins are found in the
disease-associated fibrils suggest that these proteins are subject to abnormally high
expression to such an extent that the chaperone and the proteosome system are
temporarily overwhelmed (Lansbury, 1999). These structures are generally described as
amyloid fibrils or plaques when they accumulate extracellularly. The term “intracellular
inclusions” has been suggested when fibrils that are morphologically and structurally
related to extracellular amyloid form inside the cell (Westermark et al., 2005). Current
focus in studying the structural aspects of amyloid aggregation states is due to their
crucial role in disorders such as Alzheimer‟s disease, Parkinson‟s disease, Huntington‟s
disease (Table 1), and diverse systemic amyloidosis (Walker and LeVine, 2000, Selkoe
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and Podlisny, 2002, Selkoe, 2003). Despite the ability of many proteins to form amyloid
fibrils, not much is known about their structures or the factors that govern their
formation. A principal unanswered question about these disorders is the nature in which
the natively soluble proteins of different primary structures undergo partial unfolding and
aberrant refolding to produce highly stable oligomers and polymers. The partially folded
forms have exposed hydrophobic regions and are therefore prone to self-aggregation
(Selkoe, 2003). An understanding of how this aggregation process happens and how the
resultant aggregates initiate cell dysfunction will offer valuable information that is
essential in the development of new therapeutic strategies for specific molecular
interventions, and treatment modalities for these disorders.

1.2 Alzheimer‟s Disease (AD)

AD is the most common cause of dementia in the elderly, and is a progressive
neurodegenerative disorder that gradually destroys cognitive function and eventually
causes death.

AD currently affects nearly 2% of the population in industrialized

countries (Mattson, 2004).

As the life expectancy of

individuals has extended

considerably, these diseases are of a major concern (Glenner, 1989), and it is estimated
that about 22 million people will be afflicted globally by 2025 [St George- Hyslop 2000].
This statistics emphasizes the need for novel and effective treatments. During the last
decade there has been expansive research in the field of AD. Microscopic studies have
revealed a loss of neurons in hippocampus, a center for memory, and the cerebral cortex,

3

Disease

Protein

Locus

Amyloid beta protein

Extracellular plaques

Tau

Tangles in neuronal

Alzheimer‟s disease

cytoplasm
Frontotemporal dementia with

Tangles in
Tau

parkinsonism

neuronal cytoplasm

Parkinson‟s disease; dementia
α-synuclein

Neuronal cytoplasm

with Lewy bodies
Extracellular plaques
Creutzfeldt-Jakob disease:
Prion protein PrPSC

Oligomers inside and

Mad cow disease
outside neurons
Polyglutamine disease;
Long glutamine stretches

Neuronal nuclei and

within certain proteins

cytoplasm

Superoxide dismutase

Nueronal cytoplasm

Huntigton‟s disease, spino
cerebellar ataxias

Amyotrophic lateral sclerosis

Table1.1 Some human brain diseases characterized by protein misfolding and
aggregation Figure adapted from Selkoe. D.J., (2003) Nature, 426: 900-904
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which is the center for reasoning memory and other thought processes. Hallmark lesions
of AD include amyloid deposits neurofibrillary tangles (NFTs) and dystrophic neuritis
(Glenner, 1989, Ballatore et al., 2007).
Immunocytochemsitry revealed that one of the earliest pathological changes
include a population of neurons packed with swollen lysosomal granules (Nixon et al.,
1992). These lysosomes or granules also stain with antibodies against Aβ (Gouras et al.,
2000, D'Andrea et al., 2001). Extracellular heparan sulfate (Perry et al., 1991, Cummings
et al., 1993) immunoreactivity, advanced glycation end products (Smith et al., 1994,
Vitek et al., 1994), racemic amino acids and isopeptide bonds (Shapira et al., 1988, Roher
et al., 1993) are found associated with senile plaques, NFTs, and dystrophic neurites.
Activated microglia are found along the margins of senile plaques (Wisniewski et al.,
1989). Key markers of inflammation are also associated with amyloid deposits
(Rozemuller et al., 1989, Dickson et al., 1993). A broad spectrum of pathological events
are associated with AD, and recent studies have indicated the possibility of AD
representing a spectrum of diseases (Hyman, 1996). These studies have also revealed
genetic causes of the disease in addition to cellular and molecular mechanisms that are
linked to AD. Until recently post mortem analysis of the brain tissue was the only way to
study the pathological features of AD. This limitation prompted research on biochemical
markers of AD in serum and cerebrospinal fluid that will be able to complement clinical
approaches and help in early diagnosis (Khachaturian, 2002). It was initially assumed
that extracellular amyloid fibrils were responsible for exerting cytotoxic effects. Over the
past decade data from cell culture models, β-amyloid precursor transgenic mice, and
studies on the human brain suggest that prefibrillar, diffusible assemblies of amyloid beta
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was also deleterious.

This has opened up a wide avenue for further probing the

mechanisms of AD.

1.3 AD Pathology

The characteristic neuropathology of AD was first described by a German
psychiatrist, Alois Alzheimer, in 1907. Two hallmark pathological findings in the brains
of AD patients are extracellular amyloid plaques, and intracellular neurofibrillary tangles
(NFTs). However, there is evidence that suggests that apart from the plaques and the
neurofibrillary tangles, a third of the AD patients will exhibit significant cerebrovascular
pathology. Cerebral amyloid angiopathy, micro vascular degeneration that affects the
cerebral endothelium and smooth muscle cells, hyalinosis and fibrosis are also seen in
AD (Vinters et al., 1996, Attems, 2005, Thal et al., 2008).

1.3.1 Extracellular Plaques

Extracellular amyloid plaques mainly constitute diffuse and neuritic plaques. The
neuritic plaques are intimately surrounded by dystrophic axons and dendrites, reactive
astrocytes and activated microglia (Selkoe, 2001). Neuritic plaques are brain lesions that
are generally found in large numbers in limbic and association cortices (Dickson, 1997).
The main protein constituent of plaques is amyloid beta (A) peptide. A peptide is a
39-43 amino acid proteolytic product of amyloid precursor protein (APP) and forms long
insoluble amyloid fibrils which accumulate as spherical microscopic deposits known as
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senile plaques.

These plaques consist of a central amorphous core which can be

identified by histological amyloid stains such as Congo red (Klunk et al., 1989) and
Thioflavin T or S (Sage et al., 1983). Plaques are surrounded by dystrophic neurites
(Glenner, 1989, Dickson, 1997) reactive astrocytes (Pike et al., 1995) and microglia
(Perlmutter et al., 1990) that are thought to release complement factors and cytokines
(McGeer and McGeer, 2001) and cause inflammatory reactions around the plaques.
Studies have established that much of the fibrillar Aβ found in neuritic plaques is
the 42 amino acid peptide Aβ(1-42). This peptide is more hydrophobic, and more prone
to aggregation than the shorter Aβ(1-40) peptide (Jarrett et al., 1993a). In the late 1980s
experimental data confirmed the presence of diffuse amyloid plaques in the same brain
region that contained many neuritic plaques (Tagliavini et al., 1988, Joachim et al.,
1989). However, further research on the diffuse plaques showed that they were the sole
form found in brain regions that lacked neuritic dystrophy, glial changes, and
neurofibrillary tangles.

In the case of healthy aged human, free of AD or other

dementing processes, studies have shown the presence of solely diffuse plaques in the
limbic and association cortices. AD patients on the other hand showed mixtures of
diffuse and neuritic plaques (Fig 1.1). It was therefore hypothesized that these diffuse
plaques represent precursor lesions of neuritic plaques (Selkoe, 2001). This hypothesis is
best illustrated by studies on Down's syndrome. Patients with Down‟s syndrome have
little or no Aβ deposition in the first decade of life, but by around 12 years of age one
begins to see diffuse plaques containing Aβ(1-42) and not Aβ(1-40). More and more
Down's subjects develop such plaques during the second and third decade of life (Lemere
et al., 1996). After the age of 30, amyloid fibril formation is seen and there is associated
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Figure 1.1.Types of Plaques Diagram showing the relationship between the subsets of
senile plaques based on the morphology of the amyloid and whether or not they are
associated with PHF type or dystrophic neurites. (Figure adapted from Dickson W D,
1997, J Neuropathol Exp Neurol, 56:321-339)
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microgliosis, astrocytosis and some neuritic dystrophy. These neuritic plaques then
become more prevalent over the next 2 decades of life.

1.3.2 Neurofibrillary Tangles

The healthy neurons in the brain are connected by axons.

Microtubules are

support structures present inside the axons that aid in the transport of molecules and
nutrients into and out of the cell.

Tau is a microtubule-associated protein and the

hyperphosphorylation of this protein leads to detachment of tau from the microtubules,
which results in the formation of neurofibrillary tangles and neurophil threads. The three
main types of neurofibrillary lesions (NFLs) based on their localizations in nerve cells
are: (i) neurofibrillary tangles (NFTs) in the cell body and apical dendrites of neurons, (ii)
neurophil threads (NTs) in distal dendrites and (iii) dystrophic neurites associated with
neuritic plaques (Tolnay and Probst, 1999). NFLs contain bundles of abnormal fibers
that consist of pairs of ~10 nm filaments wound into helices (paired helical filaments or
PHFs) as a major fibrous component, and straight 10 nm to 15 nm filaments (SFs) as a
minor component (Selkoe, 2001). Most of these filaments are highly insoluble and
resistant to detergent such as sodium dodecyl sulfate (Selkoe et al., 1982). In AD, the
hyperphosphorylated tau decreases the ability to promote the microtubule assembly and
instead aggregates into paired helical filaments (PHFs) in the cytoplasm of the
degenerating neurons (Buee et al., 2000). Neurofibrillary pathology is also found in other
neurodegenerative disorders like FTDP-17 (fronto temporal dementia and Parkinsonism
linked to chromosome 17) (Lewis et al., 2001).
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1.3.3 Relationship Between Aβ and Tau

Pathophysiological mechanisms underlying AD have been controversial. The
most dominant theory of AD etiology and pathogenesis is amyloid cascade hypothesis.
The hypothesis states that overproduction of A, or defect in the peptide clearance, leads
to amyloid deposition, which produces tangles that may lead to cell death, resulting in
memory impairment in AD (Hardy and Gwinn-Hardy, 1998, Selkoe, 2001). There is
strong evidence suggesting that A is critically involved at an early stage in the
pathogenesis of AD (Vassar, 2004), and that A accumulation precedes and promotes tau
pathology. PHF formation in AD is not due to mutations in the tau gene but is due to
cellular cascade triggered by A, which causes the abnormal phosphorylation of tau
proteins, and their assembly to filaments (Gouras et al., 2000, Greenfield et al., 2000,
Gotz et al., 2001, Lewis et al., 2001). This statement has been supported by data that
showed presence of A in the vicinity of the neurons enhanced tau phophorylation in
vitro and in vivo (Busciglio et al., 1995). Double transgenic mice expressing mutant
human tau gene (P301L) and mutant APP developed neurofibrillary tangles and
degeneration in cortical and subcortical brain regions (Lewis et al., 2001).

Further

studies on 3xTg-AD mouse harboring mutations in APP, Tau and presenilin showed that
intraneural A accumulation in cell bodies preceded tau hyperphosphorylation (Oddo et
al., 2003, Billings et al., 2005). Injection of A(1-42) into the brains of P30IL mutant tau
transgenic mice resulted in an increase in the number of NFTs by a factor of five. The
increase in the numbers were seen in the amygdale from where the neurons project into
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the injection sites (Gotz et al., 2001). These data support the fact that A is the primary
cause for the disease.

1.4 Overview of Amyloid Beta (Aβ) Peptide

1.4.1 Aβ Generation from Amyloid Precursor Protein (APP)

Amyloid beta is derived from a larger precursor protein, amyloid precursor
protein (APP), a type-I integral transmembrane glycoprotein.

APP contains an

extracellular N-terminus and a short C-terminal region that lies in the cytoplasm APP is
present in a variety of tissues but predominantly in the brain (Mattson, 1997). It is
encoded by a gene located on chromosome 21 (Masters et al., 1985). Splicing of the APP
gene gives rise to at least three transcripts that encode proteins of 695, 751 and 770
amino acids (Hardy, 1997, Selkoe, 1999). All of the APP isoforms contain the 39/43
amino acids long Aβ domain. The 695 amino acids are the main isoform expressed in
neurons (Golde et al., 1990). At present the physiological function of APP in the brain
remains unclear, although it has been proposed to have functions in transmembrane
signal transduction (Nishimoto et al., 1993), calcium regulation (Mattson et al., 1993) and
cell proliferation and adhesion (Saitoh et al., 1989). A characteristic feature of APP is its
proteolytic cleavage by group of enzymes or enzyme complexes, the α-, β- and γsecretases (Selkoe, 2001). The differential actions of these secretases lead either to the
non-amyloidogenic or amyloidogenic pathway. Three enzymes, ADAM 9, ADAM 10
and ADAM 17 (also known as tumor necrosis factor converting enzyme), all with α-

11

secretase activity, have been identified.

These belong to the ADAM family, a

disintergrin and metalloproteinase enzyme (Allinson et al., 2003).

The α-secretase

cleaves APP within the Aβ region to produce the large amino N-terminal ectodomain, the
soluble sAPP that is subsequently secreted into the extracellular medium (Kojro and
Fahrenholz, 2005), and the 83-residue COOH-terminal fragment C83 (Sisodia et al.,
1990). The C83 fragment is retained in the membrane, and subsequently cleaved by γsecretase to form the short segment p3 (Sisodia et al., 1990). The α-cleavage pathway is
considered as default, non-amyloidogenic pathway, since the cleavage occurs in the Aβ
region, thereby precluding formation of Aβ.

In the amyloidogenic pathway, initial

proteolysis is mediated by β-secretase, a type I integral membrane protein of the pepsin
family of aspartyl proteases (Vassar et al., 1999). The β-secretase cleavage produces a
99-residue COOH-terminal fragment C99 within the membrane and soluble β-APPs, in
the extracellular space (Vassar, 2004). These fragments are processed by γ-secretase to
produce p3 from C83 or Aβ from C99 (Fig 1.2). γ-secretase cleavage is not sequence
specific resulting in Aβ peptides of varying length ranging from 39-43 amino acids.
(Selkoe, 2001).

1.4.2 Aβ Fibrillogenesis

Monomeric A formed from APP cleavage is unstructured (Suzuki et al., 1994),
and can self- assemble via non-covalent nucleation dependent polymerization process
(Jarrett and Lansbury, 1993, Lomakin et al., 1996). Aβ is thought to start accumulating
in vivo as low molecular weight species (LMW Aβ) that consists primarily of monomers
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Figure 1.2 Schematic representation of formation of Aβ from APP by the action of
secretases. EC: extracellular; TM: transmembrane; IC: intracellular. Aβ domain is
highlighted in red. Only one cleavage site is shown for each enzyme. Figure adapted from
Zheng.H and Koo H.E, 2006, Mol Neurodegen, 1:5.
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that are constitutively secreted from the brain cells (Hartley et al., 1999). Formation of
Aβ consists of a change from random coil or α-helix into a β-strand. The conformational
change of β-amyloid is in part due to the hydrophobic collapse of the very hydrophobic
C-terminal region of Aβ. This limits the rate of nucleation, and the hydrophobic
interaction is further maximized by β-sheet conformation (Tycko, 2003).

Although

Aβ(1-40) residue is present in higher concentrations in the human body, elevated levels
of Aβ(1-42) residue with additional hydrophobic I41 and A42 are found to be associated
with familial forms of AD. Furthermore, it has been reported that Aβ(1-42) is the major
component of the immature senile plaques and cerebrovascular amyloid deposits (Roher
et al., 1993, Iwatsubo et al., 1994). In vitro, Aβ(1-42) forms fibrils rapidly even at much
lower concentration than Aβ(1-40) (Jarrett et al., 1993b, Harper et al., 1997a). Hence,
identification of the slowest or rate-determining step in the overall process is the key to
understanding the rate of amyloid formation.

1.4.3 Nucleation-Dependent Polymerization of Aβ
In vitro, Aβ fibrillogenesis is proposed to occur via nucleation-dependent
polymerization process.
extension phase.

This model consists of a nucleation or lag phase and an

Monomers undergo a slow nucleation phase or lag phase, which

comprise a series of association steps to form an oligomeric nucleus.

This step is

thermodynamically unfavorable, representing the rate-limiting step in amyloid fibril
formation. Once the nucleus has been formed, further addition of monomers becomes
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thermodynamically favorable, resulting in a growth phase in which the nucleus grows
rapidly to form large polymers. This is followed by a steady state phase, in which the
aggregate and the monomer appear to be at equilibrium (Fig 1.3A) (Jarrett and Lansbury,
1993, Harper and Lansbury, 1997). In nucleation dependent polymerization, polymer
formation is observed only if the monomer exceeds a certain level known as the critical
concentration. Beyond the critical concentration, the polymer concentration increases but
the monomer concentration remains the same (Harper and Lansbury, 1997). The in vivo
concentration of Aβ in the CSF is in the low nanomolar range (Nitsch et al., 1995, van
Gool et al., 1995). However, the critical concentration of Aβ measured in vitro is 3-4
orders of magnitude greater than the average brain concentration, thereby suggesting a
local super saturation mechanism for Aβ nucleus formation and growth (Harper and
Lansbury, 1997, Klunk et al., 1994). The proposed mechanism suggests that the Aβ gets
supersaturated transiently in a cellular compartment. During this period a slight increase
in the concentration results in intracellular aggregation. Also, the length of time that Aβ
is locally supersaturated is very critical. If Aβ is released from the supersaturated state
before nucleus is formed, there will be no amyloid formation as in normal conditions. In
AD, it is hypothesized that the duration of supersaturated state is lengthened thereby
leading to nucleation and amyloid fibril formation (Harper and Lansbury, 1997, Jarrett
and Lansbury, 1993, Lomakin et al., 1996), Lomakin et al., 1997).

In a typical

nucleation-dependent polymerization oligomerization is not observed until the monomer
concentration exceeds the critical concentration. During the lag phase protein associates
in a supersaturated solution to form ordered soluble oligomeric nuclei, and during this
period there are no detectable fibers. Addition of preformed protein nuclei during the lag
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Figure 1.3. Schematic representation of nucleation dependent polymerization
(A) Monomers undergo slow nucleation to form the nucleus (lag phase). Once the
nucleus is formed there is rapid aggregation to form fibrils. The lag phase can be
overcome by the addition of preformed seeds, or by manipulating the aggregation
conditions like peptide concentration, temperature, pH and ionic strength. (B) Once
critical concentration is achieved, monomers undergo nucleation to form nucleus, and
this proceeds to form the protobrils and then the mature fibrils. (Fig 1.3A adapted from
Harper. J.D., and Lansbury, P.T. Jr., 1997, Ann Rev Biochem, 66:387-407. 1.3 B adapted
from Walsh, D.M., et al 1997, J Biol Chem, 272:22364-22372).
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time results in immediate polymerization, a process known as seeding (Harper et al.,
1997a). Once the oligomeric nuclei are formed, the aggregates grow rapidly (elongation
phase) until a thermodynamic equilibrium between the aggregate and monomer is
reached (Harper et al., 1997a, Walsh et al., 1997). Studies have shown that small
elongated oligomers appear early in the fibril formation pathway, and measure 2.7 to 4.2
nm in diameter and < 200 nm in length. These structures disappeared with longer
incubation time, and were replaced by full length fibrils (Kowalewski and Holtzman,
1999). Radiochemical immunological assays have shown the existence of short lived
species prior to the formation of protofibrils, that progress to form the mature fibrils
(Walsh et al., 1997). Intermediate protofibril structures were about ~40% the height of
the mature fibril, and are believed to appear very early in the process and disapears as the
fibrils appear (Koo et al., 1999). These findings support the idea that protofibrils acts as
a center for the formation of mature fibril. Several models exist that shows the proposed
coversion of protofibrils to mature fibrils. One is the end to end association of protofibrils
but,this was considered unlikely due to the kinetic barriers associated with proper
allignment of protofibril ends (Walsh et al., 1997). Alternatively, protofibrils could also
associate laterally followed by an end-end annealing to form mature fibrils (Nichols et
al., 2002).
The longer peptide Aβ(1-42) was shown to nucleate faster than Aβ(1-40) (Harper
and Lansbury, 1997).

Transgenic mice that secrete high levels of Aβ(1-42) in the

absence of APP over expression, show greater extent of amyloid pathology in contrast to
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transgenic Aβ(1-40) mice (McGowan et al., 2005). These experiments highlighted the
importance of Aβ(1-42) in amyloid deposition, and it was suggested that Aβ(1-42) is
required for the nucleation in vivo. The exact nature of the nucleation seed in vivo is not
known. It is hypothesized that in the crowded environment inside neurons or in the brain
parenchyma, Aβ binds to other proteins or lipids and contributes to seeding (Hoozemans
et al., 2006). One such example that supports this hypothesis is the binding of Aβ to
ganglioside GM1, leading to a conformation change that likely acts as a seed for
aggregation, thereby increasing the fibril formation (Hayashi et al., 2004).
1.5 Fibril Structural Assembly

Amyloid fibrils are noncrystalline and insoluble making it difficult for structural
studies by the two principal experimental approaches to structure determination – X-ray
crystallography and solution-state nuclear magnetic resonance (NMR). However, X-ray
fiber diffraction studies indicate a cross β‟ orientation in amyloid fibrils.

Intense

synchrotron X-ray beams were used to obtain high-resolution diffraction patterns from a
range of different ex vivo and synthetic amyloid fibrils. Amyloid fibrils were isolated
from patients with monoclonal λ immunoglobulin light chain amyloidosis, reactive
systemic amyloid A protein amyloidosis and Val30Met transthyretin amyloid, synthetic
fibrils were isolated from residues 10-19 of transthyretin, and peptide was isolated from
residues 20-29 of islet–associated polypeptide (1APP) (Inouye et al., 1993, Sunde et al.,
1997).

High resolution patterns from these samples were dominated by cross beta

reflections, and the diffraction patterns showed similarities in spite of the fact that the
samples were from different peptides. This suggested the presence of a common core
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molecular structure at least at the level of protofilament. Extensive biophysical studies
were done on transthyretin, a tetrameric protein that is the backup transporter of
thyroxine and the main transporter of retinol binding protein (Blake et al., 1978). One
model that was extensively studied was the Val30Met transthyretin amyloid (Blake and
Serpell, 1996), and this model represented the basic structural elements of the other
amyloid fibrils that were studied in Sunde et al, (1997). Structure prediction studies have
indicated that C –terminal 10 residues and residues 17-21 are highly hydrophobic.
Residues 28 onwards had high probability for β-sheet structure (Kirschner et al., 1987)
The fiber diffraction studies cannot determine the chemical details required to
understand the fibrillogenesis, especially details regarding parts of the sequence that form
β-strands, and the specific amino acid residues that interact. Solid state NMR studies
(Petkova et al., 2002) have revealed that the cross-β motif in full length Aβ fibrils is
comprised of in-register parallel –β sheets. These studies have shown that the first 10
residues of Aβ(1-40) are structurally disordered in the fibrils. Further probe into the
structural aspects revealed that the residues 12-24 and 30-40 (Fig 1.4B) form two β strand segments that are separated by a “bend” segment with non-β -strand conformation
at G25, S26 and G29. The bend enables the two strands to form parallel β-sheets that are
in contact via the side chains. The resulting structure is a parallel, in register, cross β
structure with a hydrophobic core and one hydrophobic face. Fibrillization of amyloid is
generally considered to driven by hydrophobic rather than electrostatic interactions
(Halverson et al., 1990, Hilbich et al., 1991, Hilbich et al., 1992). All full-length Aβ and
Aβ fragment fibrils studied so far have been found to possess structures that maximize
hydrophobic contacts within a β -sheet. Thus, hydrophobic interactions appear to play a.
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Structure predictions of Aβ

α or β conformation

High probability for β- sheet
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Figure 1.4 (A) Structural prediction showing the region with a high propensity for
β-sheet (shown in black). The hydrophobic clusters are shown in pink. Figure adapted
from Serpell (2000) Biochim Biophys Acta 1502:16-30. (B) Structural model of Aβ(140) schematic representation of a single molecular layer, or cross-β unit. The yellow
arrow indicates the direction of the long axis of the fibril, which coincides with the
direction of intermolecular backbone hydrogen bonds. The cross-β unit is double-layered
structure, with in-register parallel β-sheets formed by residues 12–24 (red ribbons) and
30–40 (blue ribbons). Figure adapted from Petkova.et al (2002) Proc.Natl.Acad.Sci.USA,
99:16742-16747.
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large role in stabilizing amyloid fibril structures (Halverson et al., 1990, Hilbich et al.,
1991, Hilbich et al., 1992, Harper et al., 1999)

1.6 Classification of AD

Although AD is predominantly a disease of late life, there are two broad types of
AD – the familial AD (FAD) and the sporadic AD (SAD). About 5% of AD cases are
„familial‟ and occur due to mutations in the APP or in the presenilin genes. Sporadic AD
cases are thought to be chiefly associated with lack of Aβ clearance from the brain, unlike
familial AD that shows increased Aβ production (Winklhofer et al., 2008). In FAD, the
disease segregates in families, following an autosomal dominant inheritance pattern. In
SAD, no clear family history is indicated and the disease usually occurs above 60 years
of age (Price and Sisodia, 1998). Because of the variation in age at onset, AD is also
categorized into early onset and late onset forms. Both the early-onset (familial) and the
late-onset (mostly sporadic) forms of the disease have similar neurological and
histopathological changes, suggesting that the different forms of the disease have a
common pathophysiology and shared etiology (Pimplikar, 2009).

1.6.1 Genetic Mutations Linked with Early Onset AD

Three different genes have been implicated in the pathology of familial
Alzheimer‟s disease. They are: APP (mAPP) gene on chromosome 21 (Goate et al.,
1989, Levy et al., 1990), mutations in the presenilin 1 (PS1) gene on chromosome 14 and
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mutations in the presenilin 2 (PS2) gene on chromosome 1 (St George-Hyslop, 2000,
Tanzi and Bertram, 2001). Mutation in the APP gene was the first mutation associated
with FAD. Involvement of APP in FAD was suspected due to the fact that the genes
resided on chromosome 21, and people with Down‟s syndrome developed the symptoms
of AD by the age of 40 (Selkoe and Podlisny, 2002). Presenilins are transmembrane
proteins localized mainly in the endoplasmic reticulum and Golgi membranes of neuronal
and non-neuronal cells (De Strooper et al., 1998). Precise functions of presenilins are
unclear.

Several studies indicate that PS1 and PS2 are catalytic components of γ-

secretases (Haass and De Strooper, 1999, Sisodia et al., 1999).

In vitro studies

demonstrated that the pathogenic mutations in the APP and presenilin genes are
associated with abnormal processing of APP. The processing sites are either located
adjacent to the Aβ domain in APP at the β- and γ- secretase cleavage sites (Nilsberth et
al., 2001) or within the Aβ sequence at the α-secretase cleavage site. Either of these lead
to increased production and elevated plasma levels of Aβ, especially Aβ(1-42) or
increased ratio between Aβ(1-42) and Aβ(1-40) (Mullan et al., 1992, Citron et al., 1994,
Suzuki et al., 1994). The only known mutation near to the β-secretase cleavage site is the
Swedish double mutation KM → NL. This mutation increases the level of total Aβ by
increasing Aβ(1-40) and the levels of Aβ(1-42), though the increase is less in the case of
the latter. Mutations near the γ- secretase cleavage site results in an increased production
of Aβ(1-42) (Scheuner et al., 1996). However, the V715M mutation (French) results in
reduction of Aβ(1-40) levels without affecting the Aβ(1-42) levels (Ancolio et al., 1999),
suggesting that the increase in Aβ(1-42) : Aβ(1-40) ratio is important rather than the
absolute amount of Aβ(1-42).
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Intra-Aβ mutations are associated with amyloid accumulation in the cerebral
blood vessels in addition to the amyloid plaque formation. E693Q (Dutch) mutations are
associated with intracerebral hemorrhages (Levy et al., 1990).

A692G (Flemish)

mutation manifest with intracerebral hemorrhages but these patients may survive to
develop a progressive AD-like dementia (Hendriks et al., 1992). The E693G (Arctic)
mutation is associated with a decrease in Aβ(1-42) concentration in media from cells that
were transfected with APPE693G. Also, the plasma levels of both Aβ(1-42) and Aβ(1-40)
were low in mutation carriers compared to healthy family members. In vitro studies have
shown that the carriers of E693G (Arctic) mutation have a high propensity to form
protofibrils (Nilsberth et al., 2001).
Transgenic (Tg) animals carrying mutations in amyloid precursor protein and
presenilin genes displayed enhanced production and progressive aggregation of Aβ.
Mouse models have shown that Aβ(1-42) is essential for Aβ deposition not only in
parenchyma but also in vessels (Borchelt et al., 1997, Holcomb et al., 1998). These
models have established that when APP/Sw mice (producing both Aβ(1-40) and Aβ(142) are bred with mice expressing mutant PS1 (that increases brain Aβ(1-42)/Aβ(1-40)
ratio), the crossbred mice have drastically increased amyloid deposition in parenchyma
and vessels compared to single transgenic controls.

However, no significant tau

pathology or extensive neuron loss, as found in AD brain, was detected in these
transgenic animals (Games et al., 1995, Hsiao et al., 1996). Studies on mutations in APP,
PS1 and PS2 genes have provided important insights for understanding some of the key
underlying biological mechanisms of AD. All these genetic mutations lead to
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Chromosomal
Gene (and protein)

Relevance to AD pathogenesis
location
Increase in Aβ production or Aβ(142)/Aβ(1-40) ratio; mutations in the

Amyloid Precursor
Aβ sequence or close to the β and γ-

21q21.3
Protein (APP)

secretase site of APP [need beta
symbols for Abeta]
Increase in Aβ(1-42)/Aβ(1-40) ratio;
Presenilin 1 PSEN1

14q24.3

mutations throughout molecule;
enzymatic role in γ-secretase complex
Increase in Aβ(1-42)/Aβ(1-40) ratio;

Presenilin 2 PSEN2

1q31–42

mutations throughout molecule;
enzymatic role in γ-secretase complex

Table 1.2 Three genes implicated in the pathology of early onset AD
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Intra Aβ mutations

Figure 1.5 Intra Aβ mutations. Schematic representation of APP molecule illustrating
the sites of cleavage by α-, β-, γ-secretases. Localization of Aβ and p3 proteins containing
the intra Aβ mutations. [Figure adapted from Nilsberth C, et al, 2001, Nat Neurosci,
4:887-893.]
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overproduction of Aβ(1-42) in the brain before AD symptoms arise, indicating
accumulation of Aβ(1-42) as initiating factor in the pathogenesis of Alzheimer‟s disease.
APP or presenilin mutations cause chronic increase in the Aβ(1-42) levels in the brain
extracellular fluid, and inside neurons that slowly leads to the oligomerization and,
eventually, forms fibrils that deposit and later forms the mature plaques (Selkoe and
Podlisny, 2002).

FAD genetics and other mouse studies have been very useful in

research on early onset AD. However, vast majority of AD cases occur late in life, and
are influenced by both genetic and environmental factors (Bertram and Tanzi, 2008, Bu,
2009). These include the ε4 allele of the apolipoprotein E (ApoE) gene (Blacker et al.,
1998, Bu, 2009). ApoE was identified as a risk factor or a susceptibility gene for AD in
1993 (Strittmatter et al., 1993). ApoE plays a major role in lipoprotein metabolism and
cholesterol homeostasis, in the brain (Mahley, 1988). The other genetic factors are,
proteinase inhibitor α2-macroglobulin gene on chromosome 12 (Pericak-Vance et al.,
1997, Blacker et al., 1998), insulin degrading enzyme on chromosome 10 (Olson, 1998,
Vekrellis et al., 2000), low density lipoprotein receptor related protein and angiotensin
converting enzyme (Olson, 1998, Kehoe et al., 1999). So far, 20 mutations in the APP
gene, 124 mutations in the PS1gene and 8 mutaions in PS2 gene have been described
worldwide. Therefore gene-targeting strategies will help clarify the in vivo functions of
genes linked to AD. The transgenic mouse model studies will offer new opportunities to
study the evolution and character of AD-type cellular dysfunction in addition to
biochemical and cellular mechanisms of the disease. These models will also be very
useful to test the various treatment strategies for the disease.
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1.7 Amyloid Cascade Hypothesis

The amyloid cascade hypothesis was formulated more than a decade ago and
states that the neurodegenerative process comprises of series of events triggered by the
abnormal processing of the amyloid precursor protein. The main tenet of the hypothesis
is that the increased production or decreased clearance of Aβ peptides causes the disease
(Hardy and Higgins, 1992, Hardy and Selkoe, 2002). In either case there is accumulation
of Aβ(1-40) and Aβ(1-42) peptides that result in aggregation and formation of insoluble
plaques, triggering a series of deleterious changes that results in death of the neuronal
cells. Since Aβ(1-42) levels are found to be higher in AD patients, it was proposed that
increased levels of Aβ(1-42) triggered the cascade of events resulting in AD (Younkin,
1995). Over the years the hypothesis has changed with regards to the type of pathogenic
Aβ species that initiates deleterious events resulting in AD. Two primary reasons led to
this alteration in the hypothesis. First, the plaque load does not correlate with the degree
of dementia in humans (Terry et al., 1991). Also, many mouse models of AD show
memory deficits long before appearance of plaques in the brain (Lesne et al., 2008).
Second, in vivo neuroimaging techniques have shown the presence of plaques in
cognitively normal people (Nordberg, 2008, Villemagne et al., 2008). It is possible that
these people may have high risk of AD. These observations suggest that insoluble
plaques are not responsible for the pathologic cascade of events, and may in fact be
benign or even protective in nature (Caughey and Lansbury, 2003).
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1.8 Modified Amyloid Cascade Hypothesis
Intracellular Aβ is assumed to be an early event in AD pathogenesis (Fig 1.6)
prior to extracellular Aβ deposition (Wirths et al., 2004).

There is evidence for

intracellular accumulation of Aβ, in both mouse models and human AD brains, that could
contribute to disease progression (Gouras et al., 2000). The focal point is mainly on the
soluble aggregates of Aβ termed oligomers.

Oligomers were observed to occur

intracellularly (Walsh et al., 2000). Furthermore, Aβ(1-42) oligomers were found to be
potent neurotoxins in neuronal cultures at nanomolar concentrations (Lambert et al.,
1998). These oligomers were termed as Aβ derived diffusible ligands (ADDLs), and
were found to be capable of inhibiting hippocampal long term potentiation thereby
disrupting synaptic plasticity (Lambert et al., 1998, Walsh et al., 2002b). Primary
neuronal cultures from APP transgenic mice have shown that oligomeric Aβ(1-42)
redistributes from the outer membrane of the multivesicular bodies (MVB) to the inner
membranes of the abnormal endosomal organelles and microtubules, and oligomeric
forms have been observed in abnormal processes and synaptic components in the human
AD brain (Takahashi et al., 2002, Takahashi et al., 2004). Sodium dodecyl sulfate (SDS)
soluble dimeric Aβ was found to accumulate in lipid rafts in the brain tissue of APP
transgenic mice. These dimers were found to appear early on as memory impairments
become obvious, and provide a further link to the assumption that Aβ oligomers are
tightly linked to memory dysfunction in AD (Kawarabayashi et al., 2004). Dimeric
oligomeric species have been isolated from human AD brains even in the absence of
protofibrils, or fibrils (Walsh et al., 2002a, Shankar et al., 2008), and the dimers were
found to inhibit long–term potentiation. A number of other poorly characterized but
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Modified β-Amyloid Cascade

Risk Factors: Aging, Trisomy 21, APP-, PS1- and PS2- mutations




Accumulation of intracellular cellular
Aβ(1-42)/ Aβ(1-40)


Soluble extracellular
Aβ(1-42)/ Aβ(1-40)


Synapse and neuron dysfunction

Plaque formation


Synapse and neuron loss

Atrophy of distinct brain areas

Dementia and other clinical symptoms

Figure 1.6. Scheme showing the modified Aβ amyloid hypothesis. Ageing, Down
syndrome and mutant APP, PS-1 or PS-2 causes an increase in intraneuronal Aβ(1-42)
levels causing it to accumulate, leading to synaptic and neuronal dysfunction and
degeneration in brain areas responsible for distinct memory functions. In parallel,
increased secretion and deposition of Aβ(1-42) leads to extracellular plaque formation.
Aβ(1-42) plaques are dynamic structures, and can also be internalized again, thereby
increasing the intraneuronal pool of Aβ(1-42), which in turn increases the neurotoxic
intracellular events. (Adapted from Wirths.O 2004, J Neuchem, 91: 513-520)
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biochemically distinct forms of Aβ oligomers have been identified. These aggregation
species have demonstrated toxicity effects in vivo and in vitro model systems (Klein et
al., 2001, Walsh and Selkoe, 2004, Glabe, 2005, Walsh and Selkoe, 2007). Fibrillar and
pre-fibrillar oligomer species formation have been reported by (Kayed et al., 2007). The
new hypothesis suggests that Aβ formation activates the microglial cells which in turn
release neurotoxic substances such as nitric oxide, proinflammatory cytokines,
complement proteins and other inflammatory mediators leading to tau phosphorylation
and neurodegenerative changes (Akiyama et al., 2000, McGeer and McGeer, 2001).

1.9 Microglia

Microglia represent the macrophage-derived cells in the nervous system that are
capable of responding rapidly to various types of insults (Davalos et al., 2005,
Nimmerjahn et al., 2005). They are derived from a myeloid lineage and are the immune
effector cells in the brain. Microglia represent approximately 5-10% of all the glia found
in the brain and are distributed throughout the gray and white matter of the nervous
system. At rest, they are believed to play supportive roles for neurons. An inflammatory
stimulus will activate the microglia causing them to migrate to sites of injury and
subsequently transform into a macrophage-like phenotype (Bamberger and Landreth,
2001). Transformation of microglia into activated form is accompanied by the up
regulation of cell surface molecules that are involved in immune responses, secretion of
cytokines and acute phase proteins (Kalaria, 1999).

Deposition of fibrillar amyloid

deposits leads to activation of microglia, and this has been supported by a number of
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animal studies. Transgenic (Tg2576) mice overexpressing APP were generated and they
developed extensive amyloid plaques, mostly in the hippocampus and in the cortex.
Analyses of these animals revealed the presence of activated microglia surrounding the
plaques (Benzing et al., 1999, Mehlhorn et al., 2000). Aβ accumulation leads to a sitespecific activation of glia resulting in the secretion of pro-inflammatory cytokines
(Akiyama et al., 2000, Cooper et al., 2000).

The inflammatory response can be

considered as an attempt to clear the Aβ, however, an overwhelming accumulation of Aβ
will lead to a chronic proinflammatory response (Blasko et al., 2004) which causes the
defect in neuronal function.
A „microglia dysfunction‟ theory (Streit, 2004) has been proposed recently. The
theory states that many of the microglia in the AD brains are dystrophic and apoptotic
due to presence of Aβ and cellular debris, and are unable to carry out their normal
function of phagocytosis and neuroprotection. The activation of microglia in AD reflects
the ongoing pathology. Experimental data have shown that reactive microglia occur
within Aβ deposits that are associated with tissue injury and dementia ( neuritic plaques),
and not with diffuse plaques (clinically benign Aβ deposits) (Perlmutter et al., 1992,
Giulian et al., 1995, Giulian, 1999). Selectivity in the distribution of reactive microglia
suggests that a specific signal within the neuritic and core plaques triggers the brain
inflammation. Moreover the pattern of microglia distribution in AD is unique to the
disease, suggesting a very crucial role for brain inflammatory responses in the etiology of
the disease. In AD, it is believed that plaques serve as stable irritants that sets the CNS in
a chronic state of inflammation, promoting the activation and recruitment of microglia,
which in turn secretes neurotoxins (Giulian, 1999). Two in vitro models support this
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hypothesis. First, plaque fragments are engulfed within few minutes after they were
placed in cultures of human microglia (Giulian et al., 1995). The morphology changes
from resting ramified forms to reactive, amoeboid shapes. Data also suggest that plaque
activated, and not resting microglia, secrete neurotoxic substances.

Second, plaque

fragments do not show direct toxic effects on microglia depleted neuron cultures. About
50-µl to 100-µl spots of highly aggregated Aβ are placed on the floor of a cell culture
well to mimic the Aβ deposits of AD. Cultured microglia from rapid brain autopsies of
subjects with or without AD are then seeded into the well. Within days, there is a
pronounced activation of the microglia as well as clear chemotaxis to the Aβ spots. The
activated microglia, within weeks, completely cover the Aβ deposits and begin to
phagocytose them, a process that can be measured quantitatively (Rogers and Lue, 2001).
These findings support the fact that immune cells of the brain are necessary to mediate
the plaque related injury to the neurons. Activated glia contributes to neurotoxicity
through the induction of inflammatory mediators such as interleukin (IL)-1and tumor
necrosis factor-alpha (TNF α). In addition, these cytokines also mediate the expression
of the inflammatory enzyme-inducible nitric-oxide synthase (iNOS) (Akama and Van
Eldik, 2000).

1.10 Aβ Induced Inflammatory Response

The brain was believed to be immunologically privileged by virtue of two factors.
One is the blood-brain barrier, which hinders entry of humoral immune elements into the
brain. Second, it was assumed that the nervous system was unable to mount an intrinsic
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inflammatory response. However, it is now widely recognized that brain immunologic
privilege may be limited since antibodies and humoral immune cells do penetrate the
brain, (Wekerle, 2002). Innate, intrinsic, microlocalized, chronic inflammatory responses
are clearly evident in multiple neurologic disorders, especially AD (Akiyama et al., 2000,
Griffin, 2006). In vitro models have facilitated elucidation of mechanisms underlying
microglial migration, colocalization, and scavenging of Aβ deposits (Rogers and Lue,
2001).

Several groups have identified a number of inflammation-related receptors

expressed on microglia.

Among the many receptors that have been identified,

macrophage scavenger receptors (El Khoury et al., 2003), Formyl chemotactic receptors
(Lorton et al., 2000), receptor of advanced glycation end products ( RAGE) (Yan et al.,
1996), are probable important ones since they can have Aβ as a ligand. Studies have also
confirmed that Aβ induces glial activation in vivo (Weldon et al., 1998, Ishii et al., 2000).
The fibrillar conformation of Aβ seems to be a crucial feature for such cell activating
effects (Ishii et al., 2000). Alternative and classical complement pathways have been
implicated in AD pathogenesis (Rogers et al., 2002b), Akiyama et al., 2000). Fibrillar
Aβ can bind C1q, the first classical pathway component.

This leads to sequential

activation of other components of the classic pathway with the release of anaphylatoxin
(C4a and C3a) and opsonizing (C3b and iC3b) fragments (Rogers, 2008) that enhance
inflammatory mechanisms. Another mechanism of complement-mediated inflammatory
responses is the formation of C5b-9, the membrane attack complex (MAC), targeted at
cellular membranes. This assembly creates a transmembrane channel that facilitates the
diffusion of ions to and from the cytoplasm, leading to disruption of cell homeostasis.
Sufficient assembling of MAC complexes on the cell surface leads to cell lysis.
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Immunohistochemical staining of C1q was shown to be colocalized with aggregated Aβ
deposits in the AD brain, but is absent in the non demented brain (Rogers et al., 1992).
A certain degree of aggregation is required for the activation of the complement system.
The amino acids 14-26 of the antibody- independent binding site of C1q contain five
cationic side chains that are likely to become charge-coupled to four anionic side chains
within residues 1 to 16 of N-terminus of Aβ peptide (Jiang et al., 1994). Along with this
charge coupling, the hexameric structure of C1q appears to align well with adjacent C1q
binding sites when Aβ is in its aggregated cross-β-pleated sheet configuration, the
configuration that is predominant in the aggregated Aβ deposit. Once C1q has been
activated by Aβ, subsequent activation of the full classic cascade may ensue, and this has
been widely reported in Aβ -rich areas of the AD brain (Webster et al., 1995). CD14, the
receptor for lipopolysaccharide (LPS) interacts with fibrillar Aβ (Fassbender et al., 2004)
and microglia kill the Aβ(1-42) damaged neuron by a CD14 dependent process (Bate et
al., 2004).

The involvement of CD14 in Aβ induced microglia activation strongly

supports the hypothesis that innate immunity is linked with AD pathology (Fassbender et
al., 2004, Eikelenboom et al., 2006).

1.10.1 Neuroinflammation and AD Pathogenesis

One of the mechanisms underlying neurodegeneration in AD is a significant
inflammatory response to Aβ plaques. Inflammatory response to Aβ plaques are observed
in the brains of human patients (McGeer et al., 1987), and in AD transgenic mouse
models (Meyer-Luehmann et al., 2008). Neuropathological studies in human brains have
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demonstrated activation of microglial cells (McGeer et al., 1996), and these results have
been corroborated by in vitro studies in which microglial cells exposed to aggregated Aβ
have shown an overproduction of proinflamamtory cytokines that trigger the
neurodegenerative cascade in the neurons (Quintanilla et al., 2004, Orellana et al., 2005).
Further support for this concept came from data showing that individuals consuming
nonsteroidal anti-inflammatory drugs (NSAIDS) have a lower risk of AD (McGeer et al.,
2006). NSAIDS have also shown protective mechanism in animal models of AD (Yan et
al., 2003). Patients receiving systemic NSAIDS developed significantly less symptoms
of AD, suggesting that controlling inflammation in the brain helps prevent or slow down
the onset of AD (McGeer et al., 1996, Rojo et al., 2008). However, this effect is
restricted to only certain (NSAIDS) drugs (Maccioni et al., 2009). Neuroinflammation is
characterized by generation of proinflammatory mediators that are locally produced by
the host cells, thereby indicating the involvement of the innate immune system.
Inflammation associated with the brain (neuroinflammation) is different from the
peripheral inflammation. AD can be thought to be autotoxic disease in which an innate
immune system uses local phagocytes, microglia, as an effector (Maccioni et al., 2009).
In vitro studies have shown that Aβ fibrils result in microglial activation (Giulian et al.,
1996, McDonald et al., 1997). The plaque-associated microglia have dilated intracellular
channels of smooth endoplasmic reticulum containing amyloid fibrils (Wisniewski et al.,
1989, Wisniewski et al., 1992). These findings indicate the role of microglia in clearing
the Aβ by phagocytosis, which normally takes place in health (Wisniewski et al., 1991).
In AD, the microglia, found clustered around the amyloid deposits, become dysfunctional
and unable to clear the amyloid deposits (Rogers et al., 2002a), (Meyer-Luehmann et al.,
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2008). While the activated microglia fail to clear Aβ, their presence results in neuronal
damage and cognitive decline due to release of cytokines (Edison et al., 2008). Infusion
of anti-Aβ antibodies stimulates the plaque-associated activated microglia to clear the
deposits (Bacskai et al., 2001).

1.11 Modeling of Alzheimer‟s Disease

Several in vivo models have been developed that were aimed at being a replica to
the AD symptoms, and to model certain aspects of neurodegeneration, or amyloid
deposition. Mouse models that express wild type APP, APP fragments, Aβ and FADlinked mutant APP and PS1 were produced. Mice expressing both mutant PS1 and
mutant APP were shown to develop Aβ amyloidosis in the central nervous system. Coexpression of the human A246E mutant PS1 and APPswe have displayed elevated levels
of Aβ in the brain, and these mice developed several amyloid deposits, dystrophic
neurites and glial responses in the hippocampus and cortex (Borchelt et al., 1997).
Further, these studies have demonstrated that APP, PS1 and BACE1 are colocalized in
the neurites immediately proximal to the sites of Aβ formation in the brain. These
findings strengthen the concept of a neuronal origin for Aβ (Wong et al., 2002). The
triple transgenic model (3xTg-AD) (Oddo et al., 2003), harbors PS1M146V, APP (Swe) and
tauP301L transgenes, and exhibit deficits in synaptic plasticity, long term potentiation, and
deficits in long-term synaptic plasticity correlate with the accumulation of intraneuronal
Aβ. Besides, data from 3xTg-AD model suggest that Aβ pathology precedes tau
pathology by several months. In vitro models have been very useful since they constitute
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models that are able to serve as approximations of a disease. In vitro models allow
detailed study of pathological factors, and make characterization possible at a cellular
level. Rat primary septal cultures (Zheng et al., 2002) and human neuroblastoma cells
(Misonou et al., 2000) have been used to study the pathophysiological mechanisms that
are hypothesized to contribute to AD. Non transfected cell lines like differentiated PC-12
cells have been treated with Aβ(1-42) to study Aβ neurotoxicity (Bergamaschini et al.,
2002). Human SH-SY5Y cells exposed to aggregated synthetic beta-amyloid peptide
Aβ(1-42), caused a decreased solubility of tau along with the generation of PHF-like taucontaining filaments that correlates with amyloid cascade (Ferrari et al., 2003).

1.11.1 In vitro and In vivo Studies on Inflammation and AD

The in vivo inflammatory response to Aβ has been mirrored in numerous in vitro
cell model systems including both microglial and monocytic cells (Klegeris et al., 1997,
Misonou et al., 2000, Yates et al., 2000, Combs et al., 2001). Aβ is deposited in the
cerebral cortex in the AD brains, and studies have shown the presence of fibrillar Aβ
(fAβ) associated with the dystrophic neuritis (Mirra et al., 1991). Geula et al have shown
that injection of plaque equivalent concentrations (200pg) of fAβ to the cerebral cortex of
aged Rhesus or marmoset monkeys resulted in a significant neuronal loss, and induced
hyperphosphorylation of tau. Further, it was also reported that injections of fAβ in the
aged primates also resulted in the recruitment and activation of large population of
microglia (Geula et al., 1998). Recent studies have shown that low concentrations of fAβ
induced massive activation of microglia in aged rhesus cortex in addition to neuronal loss
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(Leung et al., 2009). Fibrillar Aβ serves as a ligand for both the scavenger receptor class
A (El Khoury et al. 1996; Paresce et al. 1996) and receptor for advanced glycation end
products (Yan et al. 1996).

1.12 Human Immune Response

The mammalian immune system is comprised of two branches: innate (cellular),
and adaptive immune systems. Innate immune system is the first line of host defense
against the pathogens, and is mediated by phagocytes, including the macrophages and the
dendritic cells. Innate immunity does not require prior exposure to foreign antigens to
get stimulated. Adaptive immunity is dependent upon the signals provided by the innate
immune system, which in turn facilitates expansion of antigen specific T and B
lymphocytes that can recognize infinite number of potential antigens (Kielian, 2006).
Host-defense has been based on the ability to recognize pathogen structures (Akira et al.,
2006). The innate immune system recognizes pathogens via a predetermined subset of
germ line encoded receptors, thereby limiting the ability to recognize every possible
antigen. The innate immune system focuses on few highly conserved structures that are
unique and expressed by a large group of microorganisms (Kielian, 2006).

The

conserved structural motifs are called pathogen-associated molecular patterns (PAMPS).
These bind via a limited number of germ-line encoded pattern recognition receptors
(PRRs) (Akira et al., 2006, Danilova, 2006). This attribute enables the immune system to
distinguish between self and nonself (Medzhitov and Janeway, 1997). Further, PAMPS
are essential for the microbial survival, and any mutaion or loss of pattern can be very
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lethal.

Hence, these patterns are less likely to be subjected to high mutation rates

(Medzhitov and Janeway, 1997). Among the various PAMPS available, (Fig 1.7) the
TLR-family members are pattern recognition receptors (PRRs) that collectively recognize
lipid, carbohydrate, peptide and nucleic acid structures expressed by different
microorganisms.

1.12.1 Toll Like Receptors (TLRs) as Pattern Recognition Receptors

Toll-like receptors (TLRs) are evolutionarily conserved from the worm
Caenorhabditis elegans to mammals (Hoffmann, 2003, Akira and Takeda, 2004, Beutler,
2004). TLRs are the primary mediators of the innate immune response and belong to a
class of type-1 integral membrane glycoproteins. Depending on the primary sequences,
TLRs are further divided into subfamilies. TLR1, TLR2 and TLR6 recognize lipids,
while TLR7, TLR8 and TLR9 recognize nucleic acids. TLR4 is known to recognize a
collection of different ligands, each having a different structure, such as,
lipopolysaccharides (LPS), plant diterpene pactlitaxel, fusion protein of respiratory
synctytial virus (RSV), fibronectin and heat shock protein (Akira et al., 2006). TLRs are
expressed on various immune cells, including macrophages, dendritic cells (DCs), B
cells, specific types of T cells, and even on nonimmune cells such as fibroblasts and
epithelial cells. Expressions of TLRs are modulated rapidly in response to a variety of
cytokines and environmental stresses.

Certain TLRs (TLRs 1, 2, 4, 5, and 6) are

expressed on the cell surface, others (TLRs 3, 7, 8, and 9) are found almost exclusively in
intracellular compartments such as endosomes. The most extensively studied PAMP is
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Figure 1.7 Pattern Recognition Receptors (PRRs) Pattern recognition receptors
involved in the innate immunity mediated host defence against amyloid-beta oligomers
and fibrils in brain. Figure adapted from Salminen A et al, 2009, Pro Neubiol, 87:187194
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the bacterial lipopolysaccahride (LPS), an outer membrane component of Gram-negative
bacteria. LPS is an endotoxin and the most potent immunostimulant. The lipid portion
of LPS termed “lipid A” is the portion associated with the Gram-negative bacterial
infection such as the endotoxic shock. The LPS released from the gram-negative bacteria
associates with LPS binding protein (LBP), an acute phase protein present in the blood
stream. The LPS-LBP complex binds to CD14; a glycosylphosphatidylinositol (GPI)
linked protein. CD14 is expressed on the cell surface of the phagocytes. The LPS is then
transferred to MD-2, which is associated with the extracellular portion of TLR4. These
steps are followed by the oligomerization of TLR4, a key component in LPS signaling
(Poltorak et al., 1998, Shimazu et al., 1999).
Aβ, is one among the several growing number of endogenous human molecules to
activate the human immune response (Kielian, 2006). There is increasing evidence that
suggests the involvement of aggregated Aβ in triggering the human innate immune
response. Interaction between fibrillar Aβ(1-42) and CD14 resulted in the release of
inflammatory products in primary murine microglial cells and human peripheral blood.
Also, recent data shows that aggregated Aβ(1-42) induces cytokine production via TLR2
and TLR4, in a human monocytic cell line (Udan et al., 2008). It has been reported
earlier that activated microglial cells are typically found clustered around the dense core
plaques and not around the diffuse Aβ deposits (Selkoe, 2004). These findings suggest
that the activation of the microglial cells is selective to a particular Aβ morphology.
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Figure 1.8 Potential roles of TLRs in the CNS response to infection and injury.
Microglia and astrocytes respond to numerous PAMPs, including peptidoglycan (PGN;
TLR2 agonist), double-stranded RNA (dsRNA; TLR3 agonist), lipopolysaccharide (LPS;
TLR4 agonist), and unmethylated CpG oligodeoxynucleotides and/or bacterial DNA
(CpG DNA; TLR9 agonist). The stimulation leads to the release of wide array of
proinflammatory cytokines (including TNF-α, IL-1β, and IL-12), chemokines [including
macrophage inflammatory protein-2 (MIP-2/CXCL2) and monocyte chemoattractant
protein-1 (MCP-1)], and reactive oxygen/nitrogen species [ROI/RNI; including
superoxide and nitric oxide (NO)]. There is a resultant enhancement of blood–brain
barrier (BBB) permeability. Endogenous TLR ligands may be released from injured cells
within the CNS parenchyma that may serve to augment neuroinflammation. (Figure
adapted from Kielian, T (2004 a) J Neuroinflamm 1:16.)

42

1.12.2 Proinflammatory Cytokine Markers

Ultra structural studies indicate microglia to be closely apposed to extracellular
fibrils, and are likely to be involved in a phagocytic response (Wisniewski et al., 1992).
Monocytes or macroglia have receptors for Aβ ( scavenger type and RAGE) (El Khoury
et al., 1996, Yan et al., 1996). In culture conditions the macrophages readily engulf Aβ
aggregates, and this interaction is often associated with the release of proinflammatory
cytokines, reactive oxygen species, proteases (eg.matrix metalloproteases) (Giulian et al.,
1995, Lorton, 1997).
AD brain display immunoreactivity for proinflammatory cytokines IL-1β, TNF-α,
IL-6 (Dickson et al., 1993) and IL-1α (Giulian et al., 1995, Mrak et al., 1995). In vitro
studies have demonstrated that fibrillar Aβ stimulation increases microglial/monocytic
TNF-α production (Klegeris et al., 1997, Combs et al., 2000). Increased levels of TNF-α
have been reported in the brain and plasma of AD patients (Bruunsgaard et al., 1999,
Tarkowski et al., 1999).

Transgenic mouse models have shown evidence that

inflammation and TNF-α contribute to disease progression.

Three month old mice

carrying three familial mutations (APPSwe, TauP301L, and PS1M146V) have shown
accumulation of intraneuronal amyloid immunoreactivity in regions that include
entorhinal cortex. These studies have also reported the presence of elevated TNF-α
mRNA levels in the same regions, and correlated with onset of cognitive deficits in these
mice models (Billings et al., 2005, Janelsins et al., 2005). These findings suggest the
importance of TNF-α as a valuable proinflammatory marker.
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1.13 Therapeutic Approach: Vaccination in AD

Immunotherapy is a very promising approach to target the disease causing Aβ
aggregation species. This therapy has been approached in two ways. One is by active Aβ
peptide vaccination (Schenk et al., 1999, Bard et al., 2000), and the other is passive
infusion of anti-Aβ monoclonal antibodies (Bard et al., 2000). Nasal vaccination with
synthetic copolymer used to treat MS was found to decrease senile plaques in mouse
model of AD (Frenkel et al., 2005). T-cell based vaccination with glatiramer acetate
resulted in decreased plaque formation and induction of neurogenesis in APP mice
(Butovsky et al., 2006). There is strong evidence that immune therapy of AD is able to
remove Aβ from the CNS, leading to an improvement in the cognitive decline that is
associated with AD (Glezer et al., 2007). These data justified the first clinical trial with
the active immunization in patients with mild to moderate AD. During the Phase 2 trial
of active immunization with Aβ(1-42) in patients with AD, it was observed that about 6
% of the patients developed a T-cell mediated, autoimmune meningoencephalitis, and the
treatment had to be stopped (Orgogozo et al., 2003). Autopsy investigations of a few
participants showed clearance of parenchymal plaques. Amyloid clearance in these cases
was associated with microglia that showed Aβ immunoreactivity, thereby suggesting
phagocytosis. A general cognitive-status test revealed a slowing of cognitive decline in
these patients (Hock et al., 2003).

The passive infusions of anti-Aβ monoclonal

antibodies target specific epitopes within the Aβ(1-42) peptide, avoiding a possible
harmful binding to normal APP. Since immunotherapy requires repeated infusion of
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antibodies over a long period, AD patients will be able to tolerate such antibodies
provided they are of human origin (Steinitz, 2008). Immunotherapy has been successful
in affecting the Aβ oligomerization and plaque formation. The striking feature was the
clearance of early hyperphosphorylated tau in the neurons of mouse models (Oddo et al.,
2004). While trials are ongoing, the current hope is that one or more of these approaches
can slow down the progression of AD and cognitive impairment.

1.14 Aβ Polymorphism and AD Pathogenic Cascade

Post mortem data suggest that different conformations of Aβ aggregated species, and not
one particular Aβ aggregated intermediate, contribute to the disease mechanisms
involved in the pathogenic cascade of AD (Hoozemans et al., 2006). Studies have shown
that the AD brain has a wide array of polymorphic aggregated Aβ species.
Immunocytochemistry studies have shown the presence of diffuse plaques in the limbic
and association cortices, and even in the striatum and cerebellum. These diffuse deposits
appear loose and granular by light microscopy, and they lack dystrophic neuritis, altered
astrocytes and microglia.

Abundant diffuse plaques also occur in the brains of

neurologically normal elderly humans, and in children with Down‟s syndrome, leading to
the hypothesis that these are precursor lesions to the neuritic plaques. These parenchymal
deposits exist as range of species from dense core neuritic plaques containing fibrillar
structures to wispy, loose, and granular deposits (Selkoe, 2004). In vitro aggregation
studies have provided detailed understanding of the fibrillogenesis mechanisms. Many
types of Aβ assembly forms have been reported from studies using synthetic Aβ.

45

Protofibrils (Harper et al., 1997b, Walsh et al., 1997, Hartley et al., 1999, Walsh et al.,
1999), annular structures, paranuclei, amyloid derived diffusible ligands (ADDLs)
(Lambert et al., 1998, Gong et al., 2003), Aβ*56 (Lesne et al., 2006), secreted soluble Aβ
dimers and trimers (Podlisny et al., 1995, Walsh et al., 2000, Walsh et al., 2002a), and
amyloid fibrils are the different aggregation species that have been reported. Soluble
oligomers are aggregation species that cannot be separated/pelleted from physiological
fluids by high speed centrifugation (Dahlgren et al., 2002, Haass and Selkoe, 2007). The
conditions that produce these different structures are not well understood. Also, these
diverse morphologies have distinct toxic and biologic activity and not do provoke the
same in vivo response (Dahlgren et al., 2002, Walsh et al., 2002a, Deshpande et al., 2006,
Salminen et al., 2009).

Significant amount of data suggest that induction of an

inflammatory response appeared to favor a fibrillar conformation. The local acidic
environment in the brain (endosomes and lysosomes) are believed to promote Aβ fibril
formation (McLaurin and Chakrabartty, 1996), thereby inducing the nerurotoxic effects.
The objective of this study was to characterize the different Aβ aggregation
species and identify the optimal Aβ aggregation state required for the stimulation of
maximal TNF-α response in a human monocytic cell line. It is possible that in the near
future the early molecular diagnosis of AD will be based on the correlation of Aβ
structural polymorphisms and levels of proinflammatory cytokines. The results of this
study will provide further clues to unraveling the complexities of AD, and help find a
solution for early diagnosis and treatment of this disorder.
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Figure 1.9 Schematic representation of various aggregation species in Aβ(1-42)
assembly. The different species reported are annular structures, paranuclei, Amyloid
derived diffusible ligands (generally categorized as oligomers). Protofibril formation
involves structural rearrangement. The final step is the formation of the mature fibrils.
U (unstructured) α- (alpha helical structure) β (beta sheet). Figure adapted from Bitan et
al (2003) PNAS,100: 330-335
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CHAPTER 2
METHODS

2.1 Disaggregation of Aβ peptides
The main focus of our study was to determine the assembly state of Aβ
aggregation species and correlate structure with biological activity. In order to have
reproducibility in experimental trials, it was important to start the experiment with a
homogenous monomeric solution of Aβ.

Commercially purchased peptides may be

contaminated with certain levels of preexisting aggregates. These aggregates act as seeds
to accelerate the aggregation of monomeric peptides (Evans et al., 1995). Any aggregate
seed present in the solution will self assemble and alter the structure of the aggregate
being investigated. Studies indicate formation of different conformers of Aβ assemblies
from the same peptide sequence (Petkova et al., 2005). Small amounts of preformed
aggregates can compromise the experiment. Therefore, protocols that ensure a uniform
starting material are very useful when working with synthetic peptides (Chen and Wetzel,
2001).
Aβ(1-42), Aβ(1-40) was purchased from r-Peptide (Bogarth, GA, USA). Aβ(142) WT and Aβ(1-42) (L34P) were gifts from Dr Ron Wetzel, University of Pittsburgh.
The peptide powder was resuspended in 100% hexafluoroisopropanol (HFIP) to a
concentration of 1 mM for one hour to solubilize any preformed aggregates, and also
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make smaller aliquots for storage purposes.

Further, this treatment allows

“normalization” of the properties of different commercial Aβ preparations and also
avoids need for subsequent filtration steps. (Wood et al., 1996, Zagorski et al., 1999).
The peptide solutions were speed vacuum centrifuged to remove the HFIP.

It was

important to remove traces of HFIP, since low percentages of it can alter the aggregation
pathway (Nichols et al 2005). The speed vacuum centrifuged samples were stored at 20C.
An alternative method of pretreatment utilized a combination of trifluoroacetic
acid (TFA) and HFIP. TFA is known to dissolve the H-bonded protein aggregates and is
relatively volatile making its removal from solution easier. Further treatment with HFIP
will remove any traces of TFA and ensuring disaggregation of any aggregated material
left behind (Zagorski et al., 1999). This protocol was used on crude peptides Aβ(1-42),
Aβ(1-40) WT Aβ(1-40) (F4W) and Aβ(1-40) (F19W), synthesized by Dr. Fabio Gallazzi,
University of Missouri- Columbia. The peptides were resuspended in 100% TFA to a
concentration of 1mM and bath sonicated for 10 minutes, and speed vacuum centrifuged
to remove TFA. This was followed by addition of an equal volume of 100% HFIP,
followed by incubation in water bath (37C) for 1 hour, and speed vacuum centrifuged to
remove HFIP. The speed vacuum centrifuged peptide samples were stored at -20C.

2.2 Preparation of Aβ Aggregation Solutions.

Lyophilized peptides were stored as 0.25 mg aliquots.

The vials were

resuspended in sterile water, phosphate buffered saline (PBS), or Hams F12 medium with
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phenol red, as required in the experiment protocol to a final concentration of 100 µM. A
more concentrated Aβ aggregation solution of 1.2mM was made in some experiments.
For preparations in water, aliquots (0.25 mg) were resuspended in 555 µl sterile water to
a final concentration of 100 µM Aβ in a cell culture hood to maintain sterile conditions.
The aggregation reactions were initiated, and stored at appropriate temperature conditions
as required by the experiment protocol. For a more concentrated Aβ preparation the 0.25
mg vial was resuspended in 46 µl sterile water to a final concentration of 1.2 mM. For
preparations in phosphate-buffered saline (PBS), lyophilized Aβ(1-42) peptide (0.25 mg)
was resuspended in 500 µl water to a final concentration of 110 µM. The preparation
was divided into two aliquots of 250 µl each, and one was supplemented with 25 µl of
10x PBS (Hyclone) to a final Aβ concentration of 100 µM. The pH of the resulting
solution was measured using a micro pH electrode (7.1). Alternatively, aggregation
reactions in PBS were initiated by resuspending the lyophilized peptide in 100 mM
NaOH, (Aβ conc 2 mM, pH 10.2) followed by dilution into PBS (Hyclone,1X) to final
Aβ concentration of 100 µM. The measured pH after dilution into PBS was 7.4.

2.3 Preparation of Aβ-Derived Diffusible Ligands (ADDLs)

Lyophilized Aβ(1-42) r-Peptide (0.25 mg) was resuspended in 11µl dimethyl
sulfoxide (DMSO,Sigma) to a concentration of 5mM as described in (Dahlgren et al.,
2002). Ice cold Ham‟s F12 medium with phenol red (Hyclone) was added to a final Aβ
concentration of 100 µM. The peptide solution was incubated at 4C for 24 hours,
followed by centrifugation at 14,000 x g for 10 minutes.
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The supernatant after

centrifugation was labeled ADDLs. The only modification made in the protocol was the
use of Hams F 12 medium with phenol red.

2.4 Determination of pH of Aggregation Solutions.

The pH of aggregation solutions was measured using a micro pH electrode
(Thermo Scientific) connected to pH meter (AccumetR Fisher Scientific). This setup
allows pH measurements in microliter volumes. The aggregation studies were done with
samples less than 1 ml and volumes as low as 5 μl was sufficient for making pH
measurements.

2.5 SDS PAGE / Western Blotting
2.5.1 SDS/PAGE
Aβ samples (100 µM) are prepared and diluted into Laemmli sample buffer
(Biorad) 1:1 in the presence of reducing agent β-mercaptoethanol. The samples were
boiled for five minutes and 15 L loaded onto precast 18% Tris- glycine SDS
polyacrylamide gels (Biorad). Protein standards (10 L) (Biorad, Dual color, 10-250 kD)
were loaded as control. Aβ aggregation species were separated by electrophoresis in
Mini-cell (Mini-Protean, Biorad) using running buffer (25mM Tris, 192 mM glycine,
0.1% SDS, pH 8.3). Electrophoresis was carried out at 200 volts for 40 minutes. After
electrophoresis, protein gels were either visualized by Coomassie staining or blotted to
membranes for immunoreactivity detection.
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2.5.2 Western Blotting

The SDS-PAGE resolved proteins were transferred onto polyvinylidene difluoride
(PVDF) membranes (HybondTM-P, Amersham Biosciences) by electroblotting using the
tank system (OWL, BanditTM VEP-2). The PVDF membrane must be prewetted with
methanol in order to enable macromolecules in the aqueous phase to bind to the
hydrophobic surface of the membrane (Wetzel, 1999). Electroblotting was carried out at
200 -400 mA for 2 hours in transfer buffer (25mM Tris, 192 mM glycine, 10% methanol,
pH 8.3). The nonspecific binding sites on the membranes were blocked by incubating the
blots in 5% non-fat dry milk in PBS/T (Phosphate buffer saline; 6.7 mM phosphate,
140mM NaCl, and 0.1% Tween-20, pH 7.5) at 4ºC for at least an hour.

In some

experiments the blocking was done overnight at 4ºC. The membrane was treated with
primary antibody, Ab 9 (gift from Mayo Clinic, Jacksonville) diluted in 5% fat free
powdered milk in PBS/T for one hour, followed by wash (three times), each for five
minutes with PBS/T. The blots were then incubated with HRP-conjugated secondary
antibody, IgG anti-mouse (R&D systems) diluted (1:1000) in 5% fat free powdered milk
in PBS/T for one hour, followed by three five minute washes in PBS/T. All incubations
and washes were done with rocking.

Immunoreactive bands were detected using

enhanced chemiluminescence reagent (ECL, Pierce), prepared 5-10 mintes prior to the
treating the film. Exposure to (Kodak) was used to measure chemiluminescence, and
exposure time depended on strength of the signal.
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2.6 Dot Blot Assay
2.6.1 Dot-Blot Procedures
Nitrocellulose membrane was wetted with water and set on a filter paper for 5
minutes. Prior to spotting the sample the surface of the membrane was checked to see if
there were any droplets of water. Aβ (1-42) 5 μl (100 µM) was spotted allowed to stand
for 20 minutes. The membrane was blocked with 10% milk in PBS-0.2% Tween 20
(PBST) for experiments with OC immune serum and Ab 9. The concentration of Tween
was reduced to 0.01% for A11 antibody probing based on recommendations in protocol
in (Kayed et al., 2003). The blocking step was done for one hour at 4ºC. The membrane
was washed with PBST twice (each 5 minutes), and incubated with OC immune serum
(1:5000), Ab 9 antibody (1:5000), or A11 antibody (1:2000) for 1 hr with gentle shaking.
Wash procedure was done as mentioned above, and followed by incubation for one hour
with secondary antibody which is a 1:1000 dilution of an anti-rabbit IgG [HAF008, R&D
systems] for OC immune serum and A11 antibody or anti-mouse IgG [HAF007, R&D
systems] for Ab 9. Washed the membrane twice, and incubated with ECL substrate and
exposed to film for 30 seconds. All steps were done at 25C and slight modifications
were made to the protocols in (Akiyama et al., 2000, Kayed et al., 2003, Parvathy et al.,
2008).

2.6.2 Preparation of Controls for Dot Blot
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2.6.2.1 OC Positive Control
0.1 mg of lyophilized Aβ(1-42) was dissolved in 50 µl 100 % HFIP for 10–20
minutes at room temperature. The solution was transferred to a siliconized eppendorf
tube and diluted to a concentration of 80 µM in sterile water followed by 10-15 minutes
incubation at room temperature. The samples were centrifuged for 15 mins at 14,000 x g.
The supernatant was transferred to a new siliconized tube and subjected to a gentle
stream of nitrogen for 10 minutes to remove the HFIP. OC positive fibrillar oligomers
were generated by stirring sample at ~ 500 RPM using Teflon coated microstir bar for 24
hours at room temperature (Kayed et al., 2007). However, this preparation did not show
positive reaction with OC immune serum in the experiments we conducted.

2.6. 2.2 A11 Positive Control
Soluble oligomers were prepared by dissolving 0.1 mg Aβ in 40 µl 100 % HFIP
for 10-20 minutes at room temperature as mentioned above. The only difference from
above being the final concentration of Aβ (55 µM). 10 μL of monomeric Aβ solution was
added to 90 μL sterile water in a siliconized eppendorf tube to a final concentration of 55
µM, and incubated for 10-20 min incubation at room temperature. Following incubation
samples were centrifuged for 15 minutes at 14,000 x g and the supernatant fraction
(measured pH 3.3) was transferred to a new siliconized tube and subjected to a gentle
stream of N2 for 5-10 minutes to evaporate the HFIP. An aliquot was flash frozen after
this step. The samples were stirred at low speed (~ 500 RPM) using a Teflon coated
micro stir bar for 24-48 hours at 22 °C (Kayed et al., 2003). An aliquot was taken out
and flash frozen after 24 and 48 hours. The flash frozen samples were probed with A11
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antibody to test for presence of oligomers. This preparation showed reactivity to A11.
Prefibrillar oligomers have also reportedly been prepared by resuspension of Aβ(1-42) in
100 mM NaOH (Aβ conc. 2 mM), followed by bath sonication for 30 seconds. The
aggregation reaction was initiated by diluting the solution in phosphate buffered saline
(PBS) pH 7.4 and 0.02% sodium azide (Aβ final concentration 45 µM) and incubated at
room temperature for up to 96 hours. This method is a slightly modified version of
protocol from (Kayed et al., 2007). This preparation was tried as positive control for A11
antibody, but did not show reactivity. However, this preparation showed reactivity when
probed with OC immune serum inspite of being a control for oligomers.

2.7 Immunoprecipitation
Aβ aggregation solutions were resuspended to a concentration of 100 μM.
Aliquots of 60 µl was incubated with 2 µl (1:10 dilution) OC antisera (2 mg/ml) resulting
in ~1:300 dilution. The incubation was done without agitation for 1 hr at 4°C. Protein
G-sepharose beads (10 µl) in 20% ethanol suspension (fast flow, Sigma P 3296) was
added to the aggregation solution. Protein G beads were tap spun to remove ethanol, and
resuspended in same volume of water prior to treatment with aggregation solution. The
incubation with Protein-G beads was done with slow mixing for an additional 1 hr at 4°C.
Protein G is a cell wall protein isolated from Type G streptococci, and has high binding
affinity to the Fc region of immunoglobulin G (IgG) (Akerstrom and Bjorck, 1986). The
solution was centrifuged for 15 min at 18,000 x g and the supernatant (45 µl) was used to
treat THP-1 monocytes for 6 hours or 24 hours depending on the experiment protocol.
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After the incubation period the cells were spun and supernatants tested for TNF- levels.
Another aliquot (5µl) of the 18,000 x g supernatant was used to test for OC immune
reactivity by dot blot analysis. AFM image analysis was done with the spin supernatant
after dilution to a concentration of 1µM.

2.8 Atomic Force Microscopy (AFM)
An atomic force microscope is optimized for measuring surface features that are
extremely small.

A Nanoscope III multimode atomic force microscope (Digital

Instruments) was used in Tapping Mode. The images were obtained using noncontact
high frequency cantilevers (Ted Pella).

2.8.1 Preparation of sample grids for AFM
Aβ(1-42), Aβ(1-40) aggregation solutions (100 µM) were diluted to a
concentration of 1 µM. In our earlier trials we used higher concentrations (50 µM) of Aβ
and we encountered frequent damage of the cantilever. Samples were allowed to adsorb
onto mica which is known to be anatomically flat surface with hydrophilic property.
Grade VI mica (Ted Pella, Inc, Redding, CA) was cut into 11mm circles and affixed to
12 mm metal discs. Before application of sample, layers of mica was cleaved by placing
a section of one-sided scotch tape on the surface. The tape was then gently pressed and
pulled up to reveal a smooth and clean surface. Aliquots (50 µl) were applied to the
freshly cleaved mica and allowed to adsorb for 15 minutes. The solution was wicked off
from the mica surface with tissue wipe, washed with deionized water twice to remove
any unadsorbed sample, and air dried.

The prepared mica grids were stored in a
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container with desiccant. Images were obtained with a Nanoscope III multimode atomic
microscope (Digital Instruments, Santa Barbara, CA) in Tapping Mode

TM

.

Height

analysis was performed using the Nanoscope III software on flattened height modes.
Alternatively the grids were also prepared by pretreatment with 3 Aminopropyl triethoxy
silane (APTES) 99% (Sigma Aldrich). Layers of mica were cleaved as described above
and the grids were treated with APTES diluted to 100 fold in 1 mM acetic acid for 10
minutes. The APTES treated grids were washed with water and air dried. The APTES
solution is prepared fresh for each treatment. Treated mica grids were placed in disc
container overnight and 50 µl Aβ sample was applied the following day and allowed to
adsorb for 15 minutes and followed the same steps described above. For SEC fractions,
10 µl from the fractions were applied on APTES treated grids without sample dilution. A
small mark was made with a marker adjacent to the sample drop so that the grid could be
mounted appropriately for AFM imaging.

2.9 Transmission Electron Microscopy (TEM)
2.9.1 Preparation of Sample Grids for TEM.
Aβ aggregation solutions (100 µM) were diluted to 20 µM in water.
Aliquots (10 µl) were applied to 200-mesh formvar-coated copper grids (Ted Pella, Inc.).
The coating on the grid gives a shiny surface and hence can be easily identified. Samples
are applied on the shiny surface and allowed to adsorb for 10 minutes at room
temperature. Excess sample was wicked away with a tissue wipe. The samples grids
were washed three times by placing the sample side down on a droplet of water. Heavy
metal staining of the samples was done in a similar manner by incubation on a droplet of
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2% uranyl acetate (Electron microscopy Sciences, Hatfield, PA) for 5-10 minutes. The
excess stain solution was removed and the grids were air dried and stored in desiccated
containers.

The affixed samples were visualized with a JEOL JEM-2000 FX

transmission electron microscope operated at 100 – 200 k eV. The width measurements
of aggregation species were done manually.

2.9.2 Preparation of Sample Grids for Immunogold Label Studies.

Aβ aggregation solutions (100 µM) were diluted to 20 µM in water. Aliquots (10
µl) were applied to 200-mesh formvar-coated copper grids with face up (Ted Pella, Inc.).
Samples were allowed to adsorb for 10 minutes at room temperature, followed by
removal of excess sample solution with a tissue wipe. The samples grids were washed
three times by placing the sample side down on a droplet of water. The grids were
treated with primary antibody Ab9 which recognizes the amino acids 1-16 in the Aβ
peptide. Ab9 was diluted (1:1000) into sample diluent [20 mM Tris pH 7.3, 150mM
NaCl, 0.1% BSA, 0.05% Tween 20]. The grids were treated with the diluted Ab 9
preparation with the sample side down and incubated for 1 hour at room temperature,
followed by wash with water thrice. This was followed by treatment with secondary
antibody which is a solution of goat-anti mouse IgG conjugated to gold particles [Aurion
Cat #25129] diluted 1:1000 into sample diluent.

Incubation with conjugated gold

particles was also done at room temperature with the sample side down. The grids were
washed thrice with water and treated with 2% uranyl acetate solution for 5-10 minutes,
excess solution removed and the grids were air dried. The affixed samples were
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visualized with a JEOL JEM-2000 FX transmission electron microscope operated at 100
– 200 k eV (Yagi et al., 2005, Vicente et al., 2006)

2.10 Cell Culture

2.10.1 THP-1 Monocytes

THP-1 cells are cultured from the blood of patient with acute monocytic
leukemia, and have distinct monocytic markers. During culture these cells can maintain
the monocytic characteristics for over 14 months (Tsuchiya et al., 1980). THP-1 cells
were obtained from ATCC (Manassas, VA) and stored as 1 ml aliquots in liquid nitrogen
until they are required for culturing. The cells were maintained in RPMI-1640 culture
medium (HyClone, Logan, UT) containing 2 mM L-glutamine, 25 mM HEPES, 1.5 g/L
sodium bicarbonate, 10% fetal bovine serum (HyClone), 50 U/ml penicillin, 50 g/ml
streptomycin (HyClone), and 50 M -mercaptoethanol at 37oC in 5% CO2. Prior to
experiments, THP-1 monocytes were centrifuged, and the pellet was resuspended in
reduced FBS (2%) growth medium (assay medium) followed by centrifugation as
mentioned above.

Once again pellet was resuspended in assay medium, and cell

concentrations were adjusted to 1.0 x 106 cells/ml. The cell concentrations were adjusted
by counting using a hemocytometer. Depending on the protocol the THP-1 cells (0.255
ml) was added to individual wells of a 48-well sterile culture plate the final volume in the
well was 0.3 ml. The Aβ sample (45 µl) and other effectors were added to the wells and
incubated at 37C for 6 or 24 hours as per experiment protocol. For 96-well sterile
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culture plate 12 µl Aβ sample was added to individual wells containing 0.068ml cells.
The contents of each well were removed, centrifuged at 2500g for 10 min, and the
supernatant was frozen at −20°C for subsequent TNF-α measurements by ELISA
(Enzyme Linked Immunosorbant Assay).

2.10.2 Determination of TNF levels by ELISA

TNF levels were measured by using a sandwich enzyme linked immunosorbant
assay as described previously in (Udan et al., 2008). Prior to the experiment, 100 l of 4
g/ml monoclonal anti-human TNF/TNFSF1A capture antibody (R&D Systems,
Minneapolis, MN) was added to 96-well plates and incubated overnight at room
temperature. Wells were washed with PBS (HyClone) containing 0.05% Tween-20 and
blocked with 300 l PBS containing 1% BSA, 5% Sucrose and 0.05% NaN3 for an hour
at room temperature. After washing, 50 l of sample diluent (20 mM Tris containing
150mM NaCl, 0.1% BSA and 0.05% Tween 20) was added to the wells. This was
followed by addition of 50 l samples, human TNF-α standards, and incubated at room
temperature for 2 hours. Following the incubation plates were washed three times, and
the wells were next treated with 100 l biotinylated polyclonal anti-human TNF/TNFSF1A detection antibody (R&D Systems) in 20mM Tris with 150 mM NaCl and
0.1% BSA (2 hours at room temperature). In the next step, 100 L streptavidin-HRP
(R&D Systems) diluted 200 times with PBS containing 1% BSA was added and
incubated for 20 minutes at room temperature. The wells were washed as described
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above followed by addition of substrate which was 100 l of equal volumes of 3,3',5,5'tetramethylbenzidine and hydrogen peroxide (KPL, Gaithersburg, MD) for 30 minutes.
The reaction was stopped by the addition of 1% H2SO4 solution. The optical density of
each sample was analyzed at 450nm with a reference reading at 540 nm using a
SpectraMax 340 absorbance plate reader (Molecular Devices, Union City, CA).

A

standard curve was constructed by sequential dilution of a TNF- standard from 15-2000
pg/ml. The concentration of TNF- in the experimental samples were calculated from a
TNF- standard curve and the TNF- levels were normalized by dividing it with the
number of cells plated.

2.10.3 Test for Contamination by Lipopolysaccharide (LPS)

Contamination of samples with bacterial lipopolysaccharide (LPS), can give rise
to increased signals from the cells. In order to rule out any contamination, and confirm
that the proinflammatory signal was not due to LPS contamination, we added polymyxin
B sulfate PMX-B (Sigma) to the samples.

PMX-B is known to neutralize the

pathogenecity of LPS and can be used to detect any trace levels of contaminating LPS in
the Aβ(1-42) aggregation preparations (Pristovsek and Kidric, 1999). THP-1 cells were
prepared as described above, and plated on 48-well culture plate or 96 well plate. Cells
were pretreated with 0.1 µg/ml PMX-B and incubated for 30 minutes at 37C, 5% CO2.
Following incubation with PMX-B, the cells were treated with 10 ng/ml ultra pure LPS
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or Aβ(1-42) (final concentration 15 µM) and incubated for 6 hours at 37C. The cell
supernatants were collected, and stored at −20°C and analysed for TNFα levels.

2.10.4 Monocyte Adhesion Studies

2.10.4.1 Cell adhesion assay
THP-1 monocytes were prepared in reduced FBS growth medium prior to the start
of the experiment. THP-1 cells were centrifuged and resuspended in reduced FBS (2%)
growth medium, and 0.204 ml was added to individual wells of a 48-well sterile culture
plate. Cell adhesion was induced as described in (Crouse et al., 2009), by direct addition
of 10 ng/ml phorbol 12-myristate 13-acetate (PMA) (Sigma) or 15 μM Aβ peptides to
THP-1 cells.

Controls were 0.0005% DMSO for PMA and sterile water for Aβ

respectively. Cells were treated with the effectors and incubated at 37°C for 6 hours.
After the incubation period, the medium that contains non-adherent cells were removed
from the wells. The wells were washed with 200 µl of phosphate buffered saline (PBS)
and wash was collected. The cells that adhered to the plate were washed with phosphate
buffered saline (PBS, Hyclone). The adherent cells were then removed with 0.25%
trypsin-EDTA (HyClone), and counted under a microscope using a standard
hemocytometer. Percent adhesion was determined by the adherent cell number divided
by the plated cell number. We also coated the surface of 48-well cell culture plates with
human fibronectin (Fn) (Sigma). Surface coating was done by addition of 0.1 ml per well
of 50 μg/mL Fn in sterile PBS and incubation for 1 hr at 25°C. The plate was covered
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and stored at 4°C until needed for an experiment. Before the addition of cells, the excess
Fn solution was aspirated from the wells.

2.10.5 XTT Cell Viability Assay
Cell viability was monitored using an XTT (2, 3-bis (2-methoxy-4-nitro-5sulfophenyl) -2H-tetrazolium-5-carboxanilide) cell assay. XTT is a tetrazolium salt, and
is used to measure the cell metabolism of viable cells (Braeckman et al., 2002). The
assay is based on the reduction of the colorless XTT tetrazolium salt within the
mitochondria of living cells by the enzyme succinate dehydrogenase to form an orangecolored water-soluble formazan. A stock solution of XTT (Sigma) 1mg/ml was prepared
in RPMI 1640 without phenol red (Hyclone) supplemented with 2 mM L-glutamine and
stored at -20°C. Cells were treated with Aβ for 6 hours or 24 hours followed by further
incubation with final concentrations of 0.33 mg/ml XTT and 8.3 µM phenazine
methosulfate (PMS) (Acros, Morris Plains, NJ) for 3 hours at 37C. Cell supernatants
were removed from individual wells after incubation and centrifuged at 5000 rpm for 10
minutes. Supernatants were transferred to a fresh 96 well plate. The XTT reduction by
viable cells was determined by absorbance measurements of the reduced form of XTT at
467 nm.

2.11 Fast Pressure Liquid Chromatography (FPLC)
The AKTA FPLC is a type of liquid chromatography where the solvent velocity is
controlled by pumps to control the constant flow rate of solvents. The standard FPLC
consist of one or two high-precision pumps, a control unit, a column, a detection system
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(UV spectrophotometer) and a fraction collector. AKTA FPLC is controlled through
UNICORN software, which actually controls the run and offers a number of options such
as automatic detection and collection of peak fractions. The Superdex 75 HR column
was pretreated with 2 mg/ml BSA in running buffer to block non specific binding of A
aggregation species to the resin. The column was equilibrated with running buffer. The
A preparation was loaded and eluted from a Superdex 75 HR 10/30 column (GE
Healthcare) in 50 mM Tris-HCl (pH 8.0) at a flow rate of 0.5 ml/min. Monomeric
fractions were isolated by size-exclusion chromatography (SEC).

Concentrations of

monomeric Aβ isolated from the SEC elution fractions were determined by absorbance
using an extinction coefficient of 1450 cm-1 M-1 at 276 nm for Aβ(1-40) as previously
described (Nichols et al., 2002). The percentage recovery of the monomer concentration
from the column can be calculated by dividing it by the preload concentration of Aβ. The
purified monomer fractions were used to initiate aggregation the aggregation reactions.
At the appropriate aggregation time point THP-1 cells were treated with the aggregated
fractions for 6 hours and the cell supernatants were tested for TNF-α production. SEC
was also used to separate Aβ(1-42) aggregation species. Aβ(1-42) solutions (100 µM)
were allowed to aggregate at 4C for 96 hours, centrifuged for 10 minutes at 18,000 x g,
and supernatants were loaded on the column. The fractions were treated with THP-1
monocytes to test for TNF α level. Morphology studies were done using AFM and TEM.

2.12 Thioflavin-T Fluorescence Assay
Thioflavin-T (ThT) is a benzothiazole salt obtained by the methylation of
dehydrothiotoluidine with methanol in the presence of hydrochloric acid. ThT
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Fig 2.1 Structure of Thioflavin T.
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fluorescence intensity is enhanced when bound to enriched β-sheet structure found in
amyloid fibrils. This provides a simple fluorometric method for following Aβ
aggregation in prepared samples. The dye undergoes a characteristic 120 nm red shift of
its excitation spectrum that may be selectively excited at 450 nm, resulting in a
fluorescence maximum at 482 nm. The excitation and emission slits of 10 nm were used
and all measuremensts were made at room temperature. The fluorescence intensity was
monitored by excitation at 450nm and emission scan from 460-520nm using a Cary
Eclipse fluorescence spectrophotometer (Naiki et al., 1989, LeVine, 1993).

Aβ

aggregation solutions were monitored by thioflavin T (ThT) fluorescence as described in
(Nichols et al., 2005). Aβ aliquots were removed and diluted 10 fold into water, PBS
(pH 7.4), or 50 mM Tris (pH 8.0), or 150mM glycine buffer (pH 8.0) containing 5 µM
ThT. The scans were integrated from 470-500 nm to obtain ThT fluorescence values.

2.13 Centrifugation of Aβ Aggregation Solutions to Test Solubility
of Aggregation Species

2.13.1 Centrifugation at 18k, 50k, 100 k and 150 k x g
MicrofugeR 18 centrifuge, Beckman CoulterTM was moved to 4C prior to
spinning the samples. Aβ(1-42) aggregation solutions were spun for 15 minutes at
18,000 g or 14,000 g as per the experiment protocol. The spun supernatants were treated
with THP-1 cells to test for TNFα secretion. Aliquots were removed for AFM and dot
blot as per the experiment protocol. The solubility of Aβ(1-42) aggregation species were
also tested by high speed ultracentrifugation. Initial centrifugation at 50,000 x g was
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done in Sorvall RC 5B plus refrigerated centrifuge using SS-34 rotor. Since we were
working with small sample volumes (100 µl), adaptors were used. Aβ(1-42) aggregation
solutions were placed in 1.5 ml eppendorf tubes which were in turn placed in adaptors
that fit into the SS-34 rotor.

The samples were spun for an hour at 50,000 x g,

supernatants were collected,and treated with THP-1 cells to measure the proinflammatory
response. Simultaneously, samples were diluted to 1µM and applied to mica grids for
AFM image analysis.

For centrifugation at higher speeds, a refrigerated Beckman

Coulter Optima Max ultracentrifuge with TLA-120 rotor was used. The samples were
placed in polycarbonate Beckman centrifuge tubes and centrifuged for an hour at 50 k,
100 k, or 150 k x g as per the experiment protocol. The centrifugation supernatants were
collected and treated with THP-1 monocytes as described above and the supernatants
were tested for TNF-α secretion.

2.13.2 Centrifugation with Centrifugation Filter Devices

Two types of microcentrifugal devices , YM-50 with a nominal molecular weight
limit (NMWL) of 50,000 Daltons, and YM-100 with a NMWL of 100,000 Daltons were
used. The filter device has a sample reservoir that fits into a vial. The membranes used
in the micron filters are anisotrophic, hydrophillic, and has the ability to retain molecules
above a specified molecular weight. Aβ aggregation solution was pippeted into the
sample reservoir without touching the membrane with the pipette tip. The assembly was
placed in MicrofugeR 18 centrifuge, Beckman CoulterTM and spun for 15 minutes at
14,000 g. After the run the vial containing the filtrate is seperated from the sample
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reservoir. The sample reservoir was turned upside down into a new vial and then spun
for 3 minutes at 1000 x g to transfer the retentate into the vial. The supernatant and
retentate were treated with THP-1 monocytes for 6 hours. The cell supernatants were
tested for TNF-α response. Simultaneously, an aliquot was diluted to 1µM concentration
for AFM imaging. We also used centrifugal filter devices with 0.2µm pore size
(Millipore Cat # UFC30LG25). Aβ(1-42) was reconstituted in water and allowed to
aggregate for 96 hours at 4C. An aliquot was placed into the filter cup and centrifuged
for 3 minutes at 12,000 x g, the filtrate was collected and treated with cells. AFM image
analysis, Bradford assay was done with the filtrate and compared to that of the Total
(unspun sample).

2.14 Dynamic Light Scattering (DLS)

Light scattering is useful in characterizing macromolecules and colloids. This
technique can be divided into two: Static light scattering and dynamic light scattering
(DLS). Static light scattering measures the time averaged intensities of the light scattered
from a solution of particles and dynamic light scattering which measures the fluctuations
of intensities of the scattered light. Using these techniques one can obtain the weight
average molecular weight and the radius of gyration from the total intensity (static light
scattering) and the hydrodynamic (Stokes) radius (RH) from DLS (Bloomfield, 2000).
In solution the macromolecules are buffered by the solvent molecules, and the
molecules are in random motion called the Brownian motion. As light scatters from the
moving macromolecules, this motion imparts randomness to the phase of the scattered
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light. This leads to time-dependent fluctuations in the intensity of the scattered light. In
DLS the time-dependent fluctuations are measured by a fast photon counter.

The

fluctuations are directly related to the rate of diffusion of the molecule through the
solvent, and can be used to analyze the RH for the sample
DynaPro Titan Instrument (Wyatt Technology, Santa Barbara, CA) was used to
make the RH measurements. Aβ samples (30 µl) were spun at 18,000 x g for 10 minutes
and supernatant was placed directly into a quartz cuvette. The light scattering intensity
was collected at 90 angle using a 10-second acquisition time.

Particle diffusion

coefficients were calculated from auto-correlated light intensity data and converted into
RH with Stokes-Einstein equation. Histograms of percent mass vs. RH were generated
using the Dynamics software (version 6.7.1). The RH values were calculated from the
histogram.
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CHAPTER 3

CORRELATION OF Aβ AGGREGATION STATE WITH ABILITY TO INDUCE
PROINFLAMMATORY RESPONSE IN HUMAN THP-1 MONOCYTIC CELL
MODEL SYSTEM

3.1 Introduction
AD is the most frequent form of senile dementia, and is characterized by
extracellular senile plaques, and intracellular neurofibrillary tangles. The extracellular
plaques consist primarily of aggregated amyloid beta (Aβ), a 40-42 amino acid peptide
derived by the proteolysis of amyloid precursor protein (APP). Although only two amino
acids longer, Aβ(1-42) polymerizes into amyloid fibrils more rapidly than the
biologically abundant Aβ(1-40) form of the peptide (Jarrett et al., 1993b, Harper et al.,
1997a). In addition to deposition of Aβ peptides into extracellular plaques, there is also
evidence for the presence of intracellular Aβ that is believed to be initially involved in the
disease process (LaFerla et al., 2007). In vitro studies have shown that Aβ monomer will
undergo non-covalent self-assembly to form a mixture of diverse Aβ assemblies that
ultimately form insoluble fibrils (Harper et al., 1997b, Walsh et al., 1997, Harper et al.,
1999). It is assumed that the same aggregation process occurs in vivo, and these wide
ranges of morphologies appear to stimulate different types of biological responses in
vivo. Cell culture studies have demonstrated the neurotoxicity of Aβ fibrils (Pike et al.,
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1993, Lorenzo and Yankner, 1994, Seilheimer et al., 1997). Recent studies now suggest
that soluble oligomeric Aβ species may be more potent than the mature fibrils (Lambert
et al., 1998, Hartley et al., 1999, Walsh et al., 2005). Furthermore, a strong positive
correlation has been demonstrated between soluble oligomeric Aβ and severity of
dementia in humans (Lue et al., 1999).
One of the proposed mechanisms underlying progressive neurodegeneration in AD
is a chronic inflammatory response to aggregated A involving production of toxic
cytokines such as tumor necrosis factor alpha (TNF). Pathology studies have shown the
presence of inflammatory markers like activated microglia and proinflammatory
cytokines surrounding the Aβ lesions in the human AD brain (McGeer et al., 1987).
TNF is a crucial mediator of the inflammatory response. Overexpression of TNF in
the central nervous system of transgenic mouse models results in inflammation of the
CNS and neurodegeneration (Probert et al., 1995). In vitro studies have shown that
TNF stimulation of neuronal cell lines leads to increased expression of inducible nitric
oxide synthase that leads to apoptosis (Heneka et al., 1999). TNF levels are elevated in
the post mortem AD brain sections (Dickson et al., 1993) and micro vessels compared to
non AD micro vessels (Grammas and Ovase, 2001). TNFα levels are also significantly
elevated in the cerebrospinal fluid (CSF) of clinically diagnosed AD patients (Tarkowski
et al., 2003).

These findings suggest TNF levels as a valuable marker for

proinflammatory response.
Though there are several A lesions, not all of them have surrounding
inflammatory pathology (Walsh and Selkoe, 2007). The exact mechanism by which A
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causes neurodegeneration is still not clear. Understanding the molecular structure of
amyloid fibrils has attracted tremendous attraction over the past several years. These
studies have shed light on issues such as the nature of the intermolecular interactions that
stabilize amyloid structures (Tycko, 2004). Moreover, in vitro aggregation studies have
provided useful information regarding fibrillogenesis mechanisms. These studies have
provided information about the various A species that are formed along the aggregation
pathway, and how they vary in size, length, solubility and morphology (Harper et al.,
1997b, Walsh et al., 1997, Harper et al., 1999, Walsh et al., 1999, Stine et al., 2003).
Further characterization of A aggregation species will therefore enable identification of
the particular A assembly state that triggers the inflammatory mechanisms in AD.
Our objective in this study was to investigate the A structure-function relationship
through modulation of Aβ aggregation conditions by varying several factors including
peptide concentration, peptide length and temperature. Synthetic Aβ peptides. were used,
and characterization of the aggregation species were done using biophysical and
biochemical techniques in an effort to identify the Aβ assembly state that induces
maximum proinflammatory response in human THP-1 cell line. Our data indicate that an
intermediate fibrillar oligomeric aggregation species is optimal for inducing maximum
proinflammatory response in THP-1 immune cell model system. These data will provide
additional information towards understanding the relationship between inflammation and
AD. The data from this study will subsequently provide clues to the development of
therapeutic strategies to treat AD patients. This work was done in collaboration with
Maria Udan, University of Missouri, Saint Louis.
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3.2 Cell Model System for Inflammatory Studies

THP-1 human monocyte cells were used as a model system to study the
proinflammatory response. THP-1 cells attain a microglia-like morphology when treated
with lipopolysaccharide (LPS), a bacterial toxin (Yates et al., 2000), and hence, serves as
a model of primary human microglial cells. Human microglial cells are very difficult to
obtain in large quantities, while the THP-1 cells are easy to grow and can be obtained in
large quantities. Previous studies have shown that both LPS and Aβ are capable of
activating THP-1 cells, and stimulate cytokine production (Klegeris et al., 1997, Yates et
al., 2000, Combs et al., 2001).

3.3 Probing Aβ Aggregation State that Induces Maximum
Proinflamamtory Response

3.3.1 TNFα Production is Influenced by Aβ(1-42) Aggregation State

Deposition of Aβ(1-40) and Aβ(1-42) peptides in the form of senile plaques is a
neuropathological hallmark of AD. Aβ(1-42) in the fibrillar form is abundant in the
senile plaques. Aβ(1-40) also has the tendency to form fibrils, but to a lesser extent
(Iwatsubo et al., 1994). We wanted to test the ability of Aβ(1-42) to stimulate the THP-1
cells for proinflammatory response. Aβ(1-42) forms aggregates very quickly and hence it
was important to control the rate of aggregation in order to study the various species
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along the fibril formation pathway.

The initial phase of Aβ(1-42) oligomerization

involves the formation of pentamer units, hexamer units, and paranuclei. These associate
to form large oligomers and protofibrils that elongate to form mature fibrils (Bitan et al.,
2003)
In our initial studies, Aβ(1-42) reconstituted in DMSO was used and aggregation
reactions were followed by ThT fluorescence measurements. Though ThT fluorescence
values confirmed the progress of aggregation, there was inconsistency in the biological
activity. Some Aβ(1-42) preparations in DMSO were able to induce considerable activity
while the others did not (data not shown). A different protocol capable of generating
monomeric starting material was employed.

The commercially available Aβ(1-42)

peptide was treated with HFIP, vacuum centrifuged and stored as described in Methods.
Aβ(1-42) aggregation reactions were set up by reconstituting the vacuum centrifuged
peptide film in sterile water to a concentration of 100 µM and incubated at 4C. Aliquots
were removed periodically at 48, 72, 96, 120, 144, 168, 192 and 216 hours and treated
with THP-1 monocytes with cell concentration of 1 x106 cells/ml for 6 hours as described
in Methods. The cell supernatants were tested for the ability to stimulate TNF
production. We observed that freshly reconstituted Aβ(1-42) induced secretion of very
small amounts of TNF. The TNF levels in the freshly reconstituted Aβ(1-42) varied
amongst trials, but the levels were consistently low. However, we found a significant
increase in TNF levels at the intermediate time points (48-72hours) of the aggregation
reaction (Fig 3.1). Continued aggregation at 4C showed a decrease in the
proinflammatory response after 96 hours, and the signal diminished by 216 hours (Fig
3.1).
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Figure 3.1 Proinflammatory activity of Aβ(1-42). Aβ(1-42) was reconstitued in water
to a concentration of 100 μM and stored at 4oC, as described in the Methods. THP-1
monocytes were incubated with Aβ(1-42) to a final concentration of 15 μM. Aliquots
were removed immediately after reconstitution, and at 48, 96 and 216 hours of incubation
at 4oC, treated with THP-1 cells, incubated for 6 hours at 37oC, 5% CO2. After 6 hours
incubation, supernatants were collected and TNFα production was measured by ELISA.
Each line in the figure corresponds to a separate experiment. The peak response lies
between 48-96 hours of aggregation at 4oC. Courtesy Maria Udan, University of
Missouri, Saint Louis.
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The data from multiple experiments led us to hypothesize that an intermediate
aggregation species may be responsible for inducing TNF production in THP-1
monocytes.

3.3.2 An Intermediate Aggregation State Induces Maximum
Proinflammatory Response
The morphology of the aggregation species was studied using AFM. Analysis of
Aβ(1-42) aggregation time course was done in order to correlate the morphology with
ability to induce TNF production in THP-1 cells. As reported earlier (Udan et al.,
2008), we noticed small punctuate species with heights < 2 nm immediately upon
reconstitution of Aβ(1-42) (Fig 3.2, zero hour). Dynamic light scattering (DLS)
measurements of the freshly reconstituted Aβ(1-42) showed a major peak with an RH of
1.0 nm. This peak (95% mass) represents the monomeric Aβ and ensures that the starting
material is monomeric. AFM imaging of the aggregation reaction showed presence of
flexible fibrillar structures by 48 hours (Fig 3.2). These intermediate fibrillar structures
correlated with maximal TNF production by THP-1 cells. Height analyses of the fibers
were done using the Nanoscope software as described in the Methods. The fibers formed
after 48 hours of aggregation have a mean height and standard deviation (SD) of 4.2 +/1.4 nm. The lengths of the fibers ranged from 1-3 µm. Height analyses of the fibers
made at corresponding time points of cell treatment indicate no significant change in the
heights of the fibers as the aggregation proceeds from 48 hours to 216 hours. The fibers
formed at 216 hours time point had a mean height of 4.5 +/- 1.4 nm. However, the length
of the fibrils changed as the aggregation proceeds, especially fibers formed by 216 hours
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Figure 3.2. Morphology analyses of Aβ(1-42) aggregation species by AFM. Aβ(142) aggregation solutions (100 μM) in water was prepared as described in Methods,
and allowed to aggregate at 4oC. Aliquots were removed at 0, 48, 96 and 216 hours,
diluted to 1 μM with water and applied on to mica grids as described in Methods, and
imaged by AFM. Image panels are 5μm x 5μm and are shown in „height‟ mode. The
heights were measured using the Nanoscope III soft ware.
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of incubation (< 3 µm). There was a significant difference in the density of fibers. The
calculated values of the density of fibers are 1 fiber/µm2 at 48 hours of incubation and 6
fibers/µm2 at 216 hours of incubation. ThT fluorescence measurements of the
aggregation reactions were made in order to monitor the progression of the aggregation in
the reactions as mentioned in Methods. Measurements at the zero hour time point of
Aβ(1-42) solution showed no ThT fluorescence, indicating absence of aggregated
structures with β-sheet at the time of reconstitution. ThT fluorescence intensity increased
as the aggregation progressed indicating formation of β-sheet structures, and by 216
hours of incubation there was nearly 25 fold increase in the fluorescence intensities
compared to the values at start of the reaction (Fig 3.3). This correlates with the AFM
images that show formation of increased fibrillar structures by 216 hours (Fig 3.2).

3.4 Modulation of Aggregation Reaction Conditions

Aggregation of Aβ proceeds by a multistep, nucleation-dependent, process (Jarrett
et al., 1993a). In the absence of preformed fibril seed there is a significant lag period for
the formation of Aβ fibrils. Once the seeds are generated, there is rapid fibril elongation
phase. The lag time for the fibrils can be shortened by the addition of preformed fibril
seeds to monomer solutions (Jarrett et al., 1993a). The rate of Aβ fibril formation is
controlled by both fibril seed concentration and monomer concentration (Naiki and
Nakakuki, 1996). Aβ aggregation is also dependent on temperature (Harper et al., 1999)
and pH (Wood et al., 1996). The calculated pI of Aβ is 5.5, and rapid aggregation of this
peptide at pH 5.5-6.0 may be mediated by non-specific interactions of the highly
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Figure 3.3. ThT fluorescence scans of Aβ(1-42) aggregation time course. Each plot
represents a separate 100 µM Aβ(1-42) aggregation reaction. Aβ(1-42) aggregation
reactions (100 µM) in sterile water, and incubated at 4C as described in Methods. At
specific time points aliquots of Aβ(1-42) aggregation solutions were removed and mixed
with ThT diluted into water (5 µM) in a cuvette (final Aβ concentration 10 µM). ThT
fluorescence was measured as described in Methods.
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hydrophobic neutral molecules (Wood et al., 1996). In order to study the intermediates
in the slow and controlled aggregation pathway, Aβ aggregation must occur outside of
this rapid aggregation pH range. Small changes in the organelle pH, or the peptide
secretion rates might control the efficiency of fibril formation in vivo (Wood et al., 1996).

3.4.1 Increased Peptide Concentration Diminishes the Proinflammatory Signal

In Fig 3.1, we have seen that Aβ(1-42) aggregation species formed at the later time
points were not effective in inducing a proinflammatory response, suggesting that
continued aggregation diminishes the response. We increased the peptide concentration
by 12 fold in order to increase the aggregation kinetics so that the lag time for nucleation
is shortened. This step will cause rapid polymerization and fibril formation. The more
concentrated solution of Aβ(1-42) (1.2 mM) was incubated at 25 C and the cells were
treated with the same final concentration of 15µM of Aβ(1-42). The Aβ(1-42) solution at
zero hour was able to induce a very small level of TNF. However, there was no
induction of proinflammatory response at 24 hours and 48 hours even though the cells
were treated with the same final concentration of 15 µM Aβ (Fig 3.4 A). The results
were very different from the 100 µM preparation wherein we were able to see the peak
response at 48 hours. AFM imaging of the concentrated samples showed the formation
of small fibrillar structures at the time of reconstitution (Fig 3.4 B) and by 24 hours there
was rapid fiber formation. Height analyses of the concentrated Aβ(1-42) fibers were not
possible due to severe overlapping of fibers. However, the density was calculated to be 6
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Figure 3.4. Increase in Aβ(1-42) peptide concentration decreases TNF-α signal
Panel A. Two Aβ(1-42) aggregation reactions were set up. Aβ(1-42), 100 µM (triangles)
was incubated at 4oC, and the concentrated Aβ(1-42) 1.2 mM (circles), was incubated at
25oC. At specific time points aliquots were removed from the two samples and treated
with THP-1 cells with final Aβ concentration of 15 µM. Courtesy Maria Udan. Panel BC. Representative AFM images of the concentrated 1.2 mM Aβ(1-42) sample. At
specific time points aliquots were removed and diluted to final concentration of 1 µM and
applied to grids as described in Methods. B. Aβ(1-42), 1.2 mM sample aliquot taken
shortly after reconstitution and C, Aβ(1-42), 1.2 mM sample after 24 hours incubation at
25oC.
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Figure 3.5 Concentrated peptide solutions show high ThT fluorescence. Two
lyophilized aliquots of Aβ(1-42) were reconstituted to 0.1 mM incubated at 4C (circles)
or 1.2 mM incubated at room temperature (diamonds). ThT fluorescence was measured
at different time points by mixing Aβ(1-42) (10 µM) with ThT (5 µM) as described in
Methods.
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fibers per square micron after 24 hours incubation. This was comparable to the fiber
density at 216 hours aggregation of Aβ(1-42) (100 µM). We have already seen from Fig
3.1 that the 216 hour sample with the same density of fibers did not stimulate the cells for
a response. It is possible that an increase in the peptide concentration caused rapid
aggregation so that the transient intermediate species were either not formed, or were
immediately converted into the higher aggregated form. ThT fluorescence measurements
were 10 times higher in the 1.2 mM solutions than in the 100 µM solutions indicating
rapid formation of β-sheet structures in the 1.2 mM sample compared to the less
concentrated peptide solution (Fig 3.5).

3.4.2 Incubation of Aβ(1-42) at Higher Temperatures Diminishes
Proinflammatory Response

Previous studies have shown that elongation rates of Aβ fibrils vary dramatically
with temperature (Kusumoto et al., 1998). The aggregation rate of 100 µM sample was
accelerated by incubation at higher temperatures. Three aggregation reactions of 100 µM
Aβ(1-42) were prepared and incubated at 4C, 25C, or 37C. Aliquots were taken from
the reactions, treated with cells at final Aβ(1-42) concentration of 15 µM, and tested for
ability to induce proinflammatory response. Only the reaction set up at 4C stimulated
the cells for a response, while the reactions set up at 25C or 37C significantly
diminished the ability to stimulate THP-1 cells for TNFα production (Fig 3.6 A). The
aggregation reactions were monitored by ThT fluorescence measurements (Fig 3.6 B).
ThT fluorescence values were high for the aggregation at 37C with a peak at 96 hour
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Figure 3.6 Incubation at higher temperatures accelerates aggregation, but
diminishes proinflammatory activity. Panel A. A solution of Aβ(1-42), 100 µM was
separated into three tubes and incubated at three different temperatures 4oC (circles),
25oC (triangles) and 37oC (diamonds). At various time points aliquots were removed for
treatment with THP-1 monocytes. Secreted TNFα measurements for each time point were
determined by ELISA. Courtesy Maria Udan. Panel B. ThT fluorescence measurements
were made at specific time points as described in Figure 3.3.
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time point. The ThT fluorescence values did not correlate with TNFα levels. In Fig 3.6
(Panel B) the highest ThT fluorescence intensities were recorded for the sample
incubated at 37C. However, the same sample did not stimulate the cells for high TNFα
secretion. AFM images of the aggregation time course showed differences in the extent
of aggregation. The peak TNFα response form the cells was at 96 hours, hence, we
obtained the height analyses of the fibrils incubated at different temperature for this time
point. The images of Aβ(1-42) at 4C contained long flexible fiber structures with a
mean height of 5.5 +/- 1.6 nm (SD) along with the globular species (Fig 3.7 E). The
sample at 25C displayed increased number of fibers with a mean height of 6.9 +/- 2.1
nm. There was disparity in the measured fibrils heights. Also, there was an increase in
fibers with height < 5 nm (Fig 3.7 F). The AFM image of sample incubated at 37C
showed less number of fibrils, and the average height of the fibrils were 6.1+/- 1.6 nm
(Fig 3.7 G). The heights were not very different from the 25C aggregation reaction.
However, the striking feature was the absence of globular species. The fibrils formed at
37C had a twisted appearance, and shorter than the ones formed at the other two
temperatures. The decrease in the number of fibrils could possibly be due to decreased
adsorption to the mica surface. These data suggest that the proinflammatory response
corresponded with the formation of the initial intermediate fibrillar structures of Aβ(1-42)
solution that was incubated at 4C.

This finding was further strengthened by the

observation that continued, accelerated, or increased fibril formation abolished the ability
of Aβ(1-42) to stimulate the THP-1 monocytes to induce TNFα production.
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Figure 3.7. Increasing the temperature of aggregation reactions failed to invoke
TNFα response in THP-1 monocytes. 100 μM Aβ(1-42) was prepared in water (100
µM), and incubated at 4oC, 25oC or 37oC. A-G. Representative AFM images of
freshly prepared (A), 48 hours (B-D) or 96-hours (E-G) aggregation. B and E are the
images of Aβ(1-42) aggregation solution incubated at 4oC, (C and F) are images of
25oC incubation, and (D and G) are images of 37oC incubation. Heights were
determined using the Nanoscope software as described in Methods.
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3.4.3 Proinflammatory Activity is Dependent on Peptide Length

Aβ is formed from APP by the action of α- β- γ- secretases. The action of γsecretases results in the formation of Aβ peptides of different fragments of 39-42 amino
acids long (Selkoe, 2001). Among the fragments formed, the most abundant is Aβ(1-40)
fragment.

Among others, Aβ(25-35) fragment is the shortest peptide sequence that

retains the biological activity comparable to Aβ(1-42) and exhibits β-sheet aggregated
structures (Pike et al., 1995, D'Ursi et al., 2004). Aβ-(25-35) is present in plaques and
degenerating hippocampus neurons in the AD brains and not in age matched control
subjects. Aβ(25-35) has a high tendency to quickly assemble into insoluble aggregates
(Clementi et al., 2005). Our results so far indicate that Aβ(1-42) incubated at 4C formed
a species that induces maximum proinflamamtory stimulus. We wanted to test if length
of the peptide is crucial for the proinflammatory stimulus. Aβ(1-40), Aβ(25-35) peptide
fragments were selected for the experiment and compared to the response from Aβ(1-42)
under similar conditions. Three separate reactions (100 µM) of these three peptides were
set up and allowed to aggregate at 4C. The aggregation reaction was monitored by
making ThT fluorescence measurements at specific time points.

At specified time

intervals the cells were treated separately with each of the three peptides and tested for
TNFα production. ThT measurements indicate that under similar conditions Aβ(1-40)
and Aβ(25-35) did not aggregate as fast as the longer peptide Aβ(1-42) (Fig 3.8). The
supernatants from the THP-1 cells treatment indicated that only Aβ(1-42) aggregation
solution incubated at 4C stimulated the cells and were consistent with our previous data.
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Figure 3.8. Shorter Aβ peptide aggregates at a slower rate under similar
conditions. Three aggregation reactions were set up by reconstituting Aβ(1-42)
(circles), Aβ(1-40) (squares) and Aβ-(25-35) (inverted triangles) in water to a
concentration of 100 µM. The aggregation reactions were allowed to incubate at
4C. At specific time points ThT fluorescence was measured by mixing Aβ (10
µM) with ThT (5 µM) as described in Methods.
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Aβ(1-40) and Aβ(25-35) aggregation reactions were not able to induce TNFα production
in THP-1 cells under similar conditions (data not shown). Therefore, to probe further we
used Aβ(1-40) aggregation reactions set up at different temperatures. Solutions of Aβ(142) and Aβ(1-40) (100 µM) were prepared. The Aβ(1-42) solution was incubated at 4C
while Aβ(1-40) was incubated at 4C, 25C, or 37C. THP-1 monocytes were treated
with aliquots from the aggregation solutions with final Aβ concentration at 15 µM. Only
Aβ(1-42),aggregation reaction set up at 4C effectively stimulated the cells for TNFα
production (Fig 3.9). AFM (Fig 3.10) images indicate fibril formation by Aβ(1-40)
sample incubated at the three different temperatures (Fig 3.10 A-C), but at a much slower
rate compared to Aβ(1-42) (Fig 3.7 E-G). Height analyses of these images indicate that
fibrils were longer (> 5 µm) and only one or two fibrils could be located in a 5 µm x 5
µm image panel. The heights of these fibrils were slightly greater than Aβ(1-42) fibrils,
measuring 5.9 +/- 1.7 nm (SD) at 96 hours (Fig 3.10 D). There was very little change in
the fibril heights from 96 hours to 216 hours, but they were slightly longer at 216 hours
(Fig 3.10 G). TEM images of the same Aβ(1-40) aggregation reactions also displayed
fibril formation at the different temperatures (Fig 3.11). Increased temperature resulted
in the formation of large number of fibrils as seen in the AFM images, yet these
aggregation species did not induce proinflammatory activity. Aβ(1-40) and Aβ(1-42)
oligomerize through different pathways (Bitan et al., 2003), and it is possible that Aβ(142) with the extra two amino acids forms a distinct intermediate species that is able to
stimulate a proinflammatory response. AFM and TEM image analyses indicate the
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Figure 3.9. Aβ(1-40) failed to induce proinflammatory activity on THP-1 cells.
Aβ(1-40) (100 μM) was resuspended in sterile water, and incubated at 4oC (triangle),
25oC (inverted triangle) and 37oC (diamond), as described in Methods. Aliquots from the
respective aggregation solutions were used to treat the THP-1 monocytes to a final Aβ
concentration of 15 μM for 6 hours; supernatants were collected and analyzed for TNFα
production. Aβ(1-42) 100 μM incubated at 4oC was used as a control (circles). Courtesy
Maria Udan, Universit of Missouri, St-Louis.
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Figure 3.10. Increased temperature induces formation of diverse fibrils, but fails to
stimulate inflammatory response. Aβ(1-40) (100 μM) was diluted to 1 μM and applied
on the surface of freshly cleaved mica as described in Methods. The images shown above
are representative AFM images of Aβ (1-40) samples. Panel 1 (A-C) are images after 48
hours at 4oC (A), 25oC (B) and 37oC (C). Panel 2 (D-E) are images after 96 hours at 4oC
(D), 25oC (E) and 37oC (F) and Panel 3 (G-H) images after 216 hours at 4oC (G), 25oC
(H) AFM images panels are 5 μm x 5μm.
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Figure 3.11. Aβ(1-40) forms diverse fibrils upon incubation at different
temperatures. Representative TEM images of Aβ(1-40)) samples from the same
experiment as mentioned in Figure 3.9. Aβ(1-40) (100 µM) solutions were diluted to a
concentration of 20 µM and applied to formvar coated copper grids as described in
Methods. Panel 1 (A-C) are images after 48 hours at 4oC (A), 25oC (B) and 37oC (C).
Panel 2 (D-E) are images after 96 hours incubation at 4oC (D), 25oC (E) and 37oC (F)
and Panel 3 (G-E) images after 216 hours 4oC (G), 25oC (H) and 37oC (I). The scale
bars represent 100 nm.
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formation of different diverse fibrillar forms of Aβ(1-40), but none of these aggregation
species were able to stimulate a proinflammatory response when treated with THP-1
monocytes.

3.4.4 Effect of pH, Ionic strength, and Buffer Type on Aβ(1-42) Aggregation and
Proinflammatory Activity

The morphology of Aβ aggregation species alters under varying conditions of pH
and ionic strength (Fraser et al., 1991, Harper et al., 1999). Previous studies indicate that
fibrillization of Aβ(1-40) in 0.1M HCl was highly reproducible, and was free from fibrilfibril association (Lomakin et al., 1996). The fibrils formed were also found to be
morphologically indistinguishable from those formed in vivo (Lomakin et al., 1996). In
our experiments, pH measurements of Aβ(1-42) aqueous solutions in water were done
using a microelectrode, and measured pH was 3.6.

Aggregation conditions were

modulated by preparing Aβ(1-42) aggregation solution in the physiological pH 7.4. We
hypothesized that Aβ(1-42) at higher ionic strength and neutral pH will form different
structures that may stimulate proinflammatory activity in a different way. Aβ(1-42) was
reconstituted in water (100 µM), and another preparation was made wherein Aβ(1-42)
was reconstituted in 100 mM NaOH to a concentration of 2mM Aβ, followed by dilution
into PBS to a final concentration of 100 µM. The measured pH of the solution in PBS
was 7.4. The aggregation reactions were monitored by ThT fluorescence measurements.
In all previous ThT fluorescence measurements, the aggregation of Aβ(1-42)/water
solutions were monitored by ThT solution prepared in water which maintained the acidic

119

pH. We followed this protocol inorder to rule out any change in Aβ morphology due to
change in pH. The ThT values were very low and did not correlate with the
corresponding AFM images of the same sample which showed formation of fibrils (data
not shown). However, we observed that the same Aβ(1-42)/water solution when mixed
with ThT prepared in PBS (pH 7.4), or 50 mM Tris buffer (pH 8.0) had higher ThT
fluorescence values compared to measurements made with ThT/water. We analysed ThT
fluorescence of an aggregated solution of Aβ(1-42)/water (100 µM), incubated at 4C for
96 hours with ThT solutions prepared in water, 50 mM Tris buffer (pH 8.0) and 150 mM
glycine buffer (pH 8.0) (Fig 3.12 ). We observed that ThT prepared in glycine and Tris
produced similar ThT fluorescence values that were significantly higher than ThT/water
solution (Fig 3.12).

For subsequent experiments with Aβ(1-42)/water, ThT

measurements were made with ThT prepared in Tris (pH 8.0) (Fig 3.13 A circles).
Further investigations need to be done to probe the pH dependence of ThT fluorescence
measurements. The Aβ(1-42)/PBS solutions did not stimulate the THP-1 cells for TNFα
production (Fig 3.13 B, triangles) compared to the aqueous Aβ(1-42) solution (Fig 3.13 B
circles).

The PBS samples did not adhere to the mica discs for AFM imaging,

therefore,TEM was used for morphology analyses. TEM analyses of both preparations of
Aβ(1-42) showed presence of fibrillar content (Fig 3.14). However, there were
differences in the alignment of the fibrils. The fibrils formed in the aqueous solutions
were thin and were more or less isolated (Fig 3.14 A, C), while the fibrils formed by
incubation in PBS showed lateral association (Fig 3.14 B, D). Also, there was an
increase in the number of fibrils in the PBS preparations. This may be the reason for the
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increase in ThT fluorescence values for the Aβ(1-42) solution in PBS (Fig 3.13,
triangles).

600

ThT Fluor AU

500

400

300

200

100

0

ThT-water
ThT water

ThT-Tris
ThTtris

ThT-glycine
ThT
glycine

Figure 3.12 ThT fluorescence values were significantly higher at higher pH. Aβ(142) was resuspended in water to a concentration of 100 µM and incubated at 4°C. After
96 hours of incubation at 4°C, aliquots (7 µl) were removed from the aggregation
solution and mixed with (63µl) ThT solutions that were prepared in water, 50 mM Tris
buffer (pH 8.0), and 150 mM Glycine buffer (pH 8.0). ThT fluorescence measurements
were recorded as mentioned in the Methods
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Figure 3.13. pH and ionic strength of aggregation solution influences rate of
aggregation and Aβ(1-42) proinflammatory activity. Two lyophyllized Aβ(1-42)
aliquots were reconstituted in either sterile water (circles) or 100 mM NaOH followed by
dilution into sterile phosphate-buffered saline (PBS) (triangles) to a concentration of 100
µM and incubated at 4°C. (Panel A) ThT-fluorescence measurements for both Aβ(1-42)
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solutions were made at specific time points as mentioned in the Methods. (Panel B) At
the above time points, aliquots from the two aggregation solutions were treated with
THP-1 cells to a final concentration of 15 µM Aβ(1-42). The secreted TNFα levels in
cell supernatants were measured by ELISA.
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Figure 3.14. Modulation of pH and ionic strength results in formation of fibrils that
diminish proinflammatory activity. Two Aβ(1-42) aggregation solutions were
prepared in either sterile water, or, in 100 mM NaOH followed by dilution into sterile
phosphate-buffered saline (PBS) at a concentration of 100 µM and incubated at 4°C. At
specific time points aliquots were removed, diluted to 20 µM and applied on formvar
coated grids as described in Methods. (Panel A) Aβ(1-42) in water after 48 hours and
(Panel C) Aβ(1-42) 96 hours of incubation at 4C. (Panel B and D) Aβ(1-42) in PBS
after 48 hours and 96 hours incubation at 4C. The scale bar represents 100 nm.

123

3.5 Fibrils Formed in Aqueous Solutions are Soluble and Non Toxic to THP-1 Cells

3.5.1 Test for Solubility of Proinflammatory Aggregation Species

The observations made from the aggregation modulation experiments confirm that
Aβ(1-42) prepared in aqueous solutions and stored at 4C formed a species that
stimulated the THP-1 monocytes for a proinflammatory response. Our data also indicate
that the proinflammatory activity diminished as the aggregation progressed (216 hours).
The loss of stimulatory response was based on two assumptions. One was the reasoning
that the late stage fibrils precipitated out of the solution, and hence the loss of signal. We
tested the solubility of Aβ(1-42) aggregation species prepared in aqueous solutions at
specified time points. Aβ(1-42) was resuspended in water and an aliquot was separated
and centrifuged at 18,000 x g for 10 minutes. The resultant supernatant and the unspun
(total) sample were treated with cells to test for TNFα production as described in the
Methods (Fig 3.15 A). AFM images show that fibrils were present in the supernatant
after centrifugation at 18,000 x g, indicating that fibrils do not precipitate out of solution
even at the later time points of aggregation (Fig 3.15 B). Insoluble fibrils will precipitate
when spun at 18,000 x g. Our findings confirm that fibrillar structures that stimulate the
cells for proinflammatory response were soluble since the centrifugation supernatants
were still able to activate the cells for a response (Fig 3.15 A).
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Figure 3.15. Proinflammatory response is not affected by centrifugation of
aggregation solutions at 18,000 x g. (A) Aβ (1-42) solution (100 µM) were prepared in
water and incubated at 4°C. At specific time points aliquots were removed, centrifuged at
18,000 x g for 10 minutes at 4°C. The spun supernatant (inverted triangles) and unspun
(total) (circles) were treated with THP-1 cells for 6 hours and TNFα measured in cell
supernatants Courtesy Maria Udan. At the same time points, aliquots were removed
before and after centrifugation at 18,000 x g for 10 minutes, diluted to 1 μM, and imaged
by AFM. Images are 5 μm x 5 μm. The AFM images above (B, C) correspond to total
and spun supernatant sample after 96h, and (D, E) represent total and spun supernatant
after 216 hour incubation at 4°C.
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3.5.2 Test for Toxicity of Proinflammatory Aggregation Species

Toxicity of fibrils could be a reason for the loss of inflammatory response. It was
assumed that the fibrils, especially the ones formed in the later stages, were toxic to the
cells.

We tested the toxicity of Aβ(1-42) prepared in aqueous solutions at the

intermediate and the later time points using XTT assay. The data indicates that the
intermediate and the late stage fibrils are not toxic to the cells since the mitochondrial
mediated reduction of XTT was not affected in both the samples (data not shown).

3.6 Characterization of Aβ(1-42) Proinflammatory Species

The observations made from the above experiments indicate more clearly that
when Aβ(1-42) prepared in aqueous solutions is incubated at 4C there is a specific time
period for the formation of an aggregation species that is capable of inducing a
proinflammatory response. From the cumulative data it is clear that the time period for
formation of the proinflammatory species ranges from 48-96 hours. The shift in the peak
response is attributed to variation in the Aβ(1-42) peptide lots that were purchased from
r-Peptide. These findings indicate that an intermediate Aβ(1-42) species was optimal for
inducing proinflammatory response. In order to characterize these species further we
separated the samples by SDS PAGE followed by immunoblotting with Ab 9 antibody.
Ab 9 binds to amino acid residues 1-16 of the Aβ peptide. Aβ(1-42) prepared in aqueous
solution was incubated at 4C, and aliquots of samples were snap frozen at specific time
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points and separated by SDS PAGE. The SDS PAGE resolved sample was subjected to
immunoblotting. There was no clear cut separation of aggregation species (data not
shown).
Previous studies have shown that Aβ(1-42) aggregates were soluble after
centrifugation at 16,000 x g and 100,000 x g for 30 minutes (Stine et al., 2003). Our data
clearly indicate that the fibrillar structures were soluble after centrifugation at 18,000 x g
for 15 minutes. We tested the solubility of Aβ(1-42) prepared in aqueous solutions by
ultracentrifugation at higher speeds. The peak proinflammatory response for the Aβ(142) peptide lot was at 72 hours of incubation at 4C. Hence, Aβ(1-42) solution was
reconstituted in sterile water and allowed to aggregate for 72 hours, centrifuged at high
speeds ranging from 50,000 x g to 150,000 x g for an hour at 4C. The centrifugation
supernatants were treated with THP-1 monocytes and evaluated for TNFα production.
The centrifugation supernatants at 50,000 ( Fig 3.16 A) and 100,000 x g (Fig 3.16B)
induced TNFα production in THP-1 cells and were almost similar to the unspun sample
(total).

There was small decrease in the signal for 150,000 x g spin supernatant.

Analyses of AFM images showed that high speed ultracentrifugation at 150,000 x g was
effective in removing some fibrils from the solution (Fig 13.17 D). Overall, the
ultracentrifugation data further strengthened our hypothesis that intermediate fibrillar
forms that elicited maximum proinflammatory response in THP-1 monocytes were
soluble. The data also suggests that the fibrils may spin down if spun at speeds higher
than 150,000 x g. Therefore spinning at 200-300 k for an hour could be done to confirm
the above hypothesis.
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Figure 3.16 Fibrillar structures are soluble after high speed ultracentrifugation. (A)
Aβ(1-42) was reconstituted in water (100 µM) and incubated at 4C. At specific time
points two aliquots were removed, and one was centrifuged at 50,000 x g for 1 hour at
4C. The centrifugation supernatant and total (circles) were treated with THP-1 cells as
described in Methods. (B) Aβ(1-42) was reconstituted in water (100 µM) and incubated
at 4C for 72 hours. Separate aliquots of the same solution were centrifuged for 1 hour at
4C. at 10,000 x g and 150,000 x g. The pre-centrifuge sample (Total) and the
supernatants were incubated with THP-1 cells for 24 hours. The secreted TNF α level
was measured as described in Methods. Courtesy Maria Udan
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Figure 3.17 Fibrillar species are soluble even after high speed ultracentrifugation of
Aβ(1-42) aggregation solutions. Aβ(1-42) was reconstituted in water (100 µM) and
incubated at 4C for 72 hours as described in Fig 3.15. Aliquots of the supernatant after
centrifugation at 50,000 x g, (Panel B) 100,000 x g (Panel C), and 150,000 x g (Panel D)
were diluted to 1 µM and applied onto mica grids as described in Methods. (Panel A)
Aβ(1-42), (total) after 72 hours at 4C. The AFM image panels are 5µm x 5µm.
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In order to confirm that proinflammatory response was due to intermediate fibrillar
forms, it was necessary to remove fibrils from the aggregation solution, and test the
ability of the solution without fibrils to evoke a response when treated with THP-1 cells.
Centrifugal filter devices with 0.2 µm membrane pore have been reported to filter out Aβ
(1-40) protofibrils from the aggregation solution (Lashuel and Grillo-Bosch, 2005). We
used centrifugal filter units with 0.2 µm PTFE membrane for our experiments. Aβ (1-42)
was reconstituted in water as described in Methods to a concentration of 100 µM and
allowed to incubate at 4C for 72-96 hours. An aliquot was centrifuged at 12,000 x g for
3 minutes using 0.2 µm centrifugal filter devices. The filtrate was tested for the ability to
stimulate proinflammatory response and compared to the prefiltering sample (Fig 3.18
A). AFM images indicated that the filtrate was devoid of fibrils, but at the same time
there were some globular species present (Fig 3.18 C). The unfiltered sample had both
fibrillar and globular species.

Bradford assay was done to determine the protein

concentration in the pre and post filter samples. The data showed about 35 % of Aβ
remaining in the filtrate compared to the prefiltered sample. In a separate experiment
using the 0.2 µm filter, we collected the filtrate and the retentate. The retentate was
recovered from the filter cup and imaged by AFM. The images showed the presence of
both fibrillar and globular species (data not shown). Treatment of THP-1 cells with the
filtrate resulted in complete wipe out of proinflammatory response compared to unfiltered
Aβ (1-42) solution. ThT fluorescence of the filtrate was significantly reduced (75 A.U)
in comparison to the unfiltered sample (870 A.U). Results from this experiment suggest
that the filter device is capable of removing fibrils from the aggregation solution and at
the same time the filtrate does have some nonfibrilar Aβ. The data also confirms that
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Figure 3.18 Aβ(1-42) was reconstituted in water (100 µM) and incubated at 4C for 72
or 96 hours as described in methods. An aliquot was removed from the aggregation
solution and centrifuged using 0.2 µm PTFE membrane filters at 12,000 x g for 3
minutes. (Panel A). The unspun sample (Total) and the centrifugation filtrate were
treated with THP-1 cells at a final concentration of 15 µM as described in Methods. The
cell supernatants were tested for TNFα levels by ELISA. The same samples were diluted
and applied on to mica grids at a final concentration of 1 µM for AFM imaging.C-D.
AFM images of Total (C), and 0.2 µm centrifugation filtrate (D). The images are 5 µm x
5 µm panels.
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early fibrillar forms are required for inducing a proinflammaotry response and these
fibrillar species were soluble even after ultracentrifugation at high speed.

3.7 Proinflammatory Aβ(1-42) Aggregation Species can be Recognized by Antibodies
Specific for Fibrillar Conformation
At present not much is known about the high resolution oligomeric structural
studies.

Conformation-dependent antibodies and antisera that specifically recognize

amyloid fibrils (O'Nuallain and Wetzel, 2002, Kayed et al., 2007, Moretto et al., 2007) or
prefibrillar oligomers (Kayed et al., 2003) have been reported. These antibodies have the
unusual property of recognizing generic epitopes that are associated with specific
aggregation states regardless of their amino acid sequence (Glabe, 2008). Fibrils have
been defined as insoluble material that sediments at 100,000 x g. and data indicate
existence of small soluble oligomers that can react with fibril-specific antibodies (Kayed
et al., 2007).

These studies discuss the possibility of presence of oligomers with

structural organization as that of insoluble fibrils (Glabe, 2008). These oligomers are
termed fibrillar oligomers (Kayed et al., 2007). Since fibril assembly is known to be
nucleation dependent process, it is possible that small “seed” aggregates exist in which
the peptide is organized in the same lattice structure as that of fibrils (Glabe, 2008).
(Kayed et al., 2007) used fibrillar specific antibody (OC) to distinguish between fibrillar
and the other oligomeric species. We used OC immune serum to investigate if the
aggregation species capable of inducing maximum proinflammatory response belong to
fibrillar oligomer category. Aβ(1-42) solution was allowed to age for 72 hours at 4C
following which they were subjected to immunodepletion of OC positive material as
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described in Methods. The immunodepleted supernatant (OC sup) was simultaneously
reprobed with OC immune serum and also with Ab 9 antibody, using dot blot assay. Ab
9 is a sequence specific antibody and is not dependent on the conformation. Dot blot
showed significant Aβ remaining in the supernatant probed by Ab 9. There was very
little reaction to OC immune serum (Fig 3.19 C & D). AFM image analyses showed a
significant decrease in the fibrillar and diffuse material (Fig 3.19 B) compared to total
(Fig 3.19A). We wanted to probe the OC sensitivity of Aβ(1-42) aggregation species
throughout the time course of our experiment. Aβ(1-42) solution in water was prepared
as described in Methods, and an aliquot was removed immediately upon reconstitution
and snap frozen. The remaining solution was incubated at 4C. At specific time points
aliquots were removed and probed for OC sensitivity. The samples were also probed
with Ab 9 antibody as control since it is sequence specific (Fig 3.19 E). Once we
confirmed the presence of OC sensitive species in our Aβ(1-42) aggregation solutions,
we performed immunodepletion experiment, and supernatants were treated with the cells
as described in the Methods.

The ability of OC supernatant to stimulate TNFα

production in THP-1 cells was assessed. An aliquot of the same Aβ(1-42) solution
(untreated) and Aβ(1-42) treated with rabbit IgG serum was used as control. Rabbit IgG
serum was used in order to rule out any non specific binding to fibrils. Immunodepletion
of OC-positive material in the Aβ(1-42) solution diminished the proinflammatory activity
when compared to the untreated 18,000 x g spun sample or supernatants after IP with
rabbit IgG and centrifugation at 18,000 x g (Fig 3.20 A). The same samples were probed
again with OC immune serum. The dot blot showed a reduction in the OC positive
material in the OC-immunodepleted material
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Figure 3.19. Immunoprecipitation with OC antisera depletes fibrillar oligomers and
fibrils. Aβ(1-42) was reconstituted in sterile water (100 µM) and stored at 4C for 72
hours. The solution was immunodepleted with OC antisera as described in the Methods.
(A-B) AFM Images of the untreated (total) and the immunodepleted supernatant (OC
Sup). C-D. OC Supernatant probed again with OC antisera (C) and Ab-9 (D) by Dot blot
assay. E-F Aβ(1-42) was reconstituted in sterile water (100 µM) and stored at 4C. At
the above mentioned time points aliquots were removed and probed with Ab 9 and OC
antisera by Dot blot.
.

134

A

TNF
pg/106 cells

300

0

tot

tot
sup

OC IP
sup

IgG IP
sup

B

Figure 3.20. Immunoprecipitation with OC antisera reduces Aβ(1-42) induced
proinflammatory response. Aβ(1-42) was reconstituted in sterile water and incubated
at 4C for 72 hours. Aliquots of Aβ(1-42) solution were treated with OC antisera or
rabbit IgG as described in Methods. The immunodepleted Aβ(1-42) supernatants were
reprobed with OC antisera to test for OC sensitivity by dot blot. Simultaneously aliquots
were also treated with THP-1 cells and tested for TNFα secretion. (Panel A) Aβ(1-42)
untreated solution (tot), Aβ(1-42) untreated, but centrifuged at 18,000 x g and supernatant
collected (tot sup), OC immunodepletion supernatant (OC IP Sup) and rabbit IgG
immunodepleted supernatant (IgG IP Sup) were incubated with THP-1 cells for 24 hours
and the secreted TNFα was measured as described in Methods. (Panel B) Dot blot of tot
sup, OC/IP Sup and IgG IP Sup probed with OC antisera.
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compared to the 18,000 x g spun supernatants or the supernatants after IP treatment with
the rabbit IgG (Fig 3.20 B).

3.8 Size Exclusion Chromatography(SEC) of Aβ(1-42) Aggregation Species

The AFM images from ultracentrifugation experiments showed loss of fibrillar
structures in the supernatant after centrifugation at both 100,000 x g and 150,000 x g.
The loss of fibrils in the supernatants was higher in the case of centrifugation at 150,000
x g. In spite of this decrease in the fibrils, the cellular activity did not show a drastic
decrease in the proinflammatory signal. It has been discussed earlier that insoluble fibrils
sediment when centrifuged at 100,000 x g (Stine et al., 2003). Therefore, it is possible
that during high speed centrifugation the insoluble fibrils were the ones that separated out
of the solution, hence, there was no significant loss of cellular activity. (Kayed et al.,
2007)) reported that SEC fractions of Aβ(1-42) showed a broad distribution of oligomer
sizes from 8 kDa to 200 kDa, and they were recognized by OC. In our experiments peak
proinflammatory activity was around 72-96 hours of Aβ(1-42) incubation at 4C. For
further characterization, Aβ(1-42) solution was reconstituted in sterile water and allowed
to incubate for 96 hours at 4C. After 96 hours, the solution was centrifuged at 18,000 x
g for 10 minutes and supernatant was loaded on to Superdex 75 column for separation of
aggregation species as described in Methods. The elution profile showed four peaks by
UV absorbance one of them being the void volume peak, an included volume that
comprised of peaks 2 and 3 and the monomer peak (Fig 3.21 A). The peak fractions (11,
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Figure 3.21 Characterization of aggregated Aβ(1-42) by SEC. Aβ(1-42) reconstituted
in sterile water was allowed to incubate at 4C for 96 hours. The solution was
centrifuged at 18,000 x g for 10 minutes and the supernatant was loaded on to Superdex
75 column. (Panel A) 280 nm absorbance elution profiles show four peaks indicated by
arrows, (1) (Vo) Void Volume, and the peaks labeled 2, 3, and monomer are the peaks for
the included volumes. The absorbance maximum for the peaks are 1.4 µM for the void,
and 5.7 µM, 3.7 µM , 18.3 µM, for the included volume. (Panel B) Select peak fractions
were probed for OC sensitivity by Dot Blot. Fractions were used for dot blot without
dilution. (Panel C) The OC positive fractions were treated with THP-1 monocytes for 6
hours, and TNFα was measured as described in Methods. (Panel D) AFM image analysis
of the peak fraction that gave maximum proinflammatory response. The image panels are
3 µm x 3 µm.
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13, 16, 19 and 21) were assessed for OC reactivity by dot-blot analysis (3.21 B). All of
the selected fractions, with the exception of the monomer, showed OC-positive material.
Selected peak fractions were treated with THP-1 monocytes to test their ability to induce
proiflammatory response. The included peak 2 (Frac 13) showed the highest levels of
TNFα secretion (Fig 3.21 C). The peak fraction that gave maximum proinflammatory
signal was analysed by AFM. Images showed the presence of large number of short
fibrillar structures which were in the range of 100-200 nm in length, and average height
(diameter) of 5.4 nm +/- 1.6 SD for n= 116 measurements.

3.9 Discussion

AD accounts for about two-thirds of the cases of progressive dementia in elderly
people (Golde, 2002). The exact sequence of events that lead to AD is still debated.
However, there is lot of evidence that supports the hypothesis that accumulation of Aβ in
the brain triggers a complex pathological cascade leading to neuronal damage and
ultimately dementia (Selkoe, 2001). One of the events within this pathological cascade is
an inflammatory response. A key finding that signals the presence of neuroinflammation
is the accumulation of reactive microglia in the degenerating areas of the brain (McGeer
and McGeer, 2004, McGeer et al., 2005). Clumps of activated microglia appear on the
senile plaques found in AD brains and also in the surrounding tissue (McGeer and
McGeer, 2004). However, very few, if any, were found in similar regions of control
brains. AD-relevant inflammation has been investigated by studying the interactions of
human brain microglia with synthetic or brain derived Aβ peptides. These studies were
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based on the pathological observations that activated microglia in the AD-affected brains
are associated with aggregated, thioflavin S-reactive, Aβ plaques (Walker and Lue,
2005). These studies indicate that microglia upon interaction with fibrillar amyloid
plaques become activated. Fibrillar Aβ aggregates cause a limitation in the phagocytosis
that leads to cell activation in a proinflammatory manner (Walker and Lue, 2005).
Studies also indicate the involvement of cytokines (Dickson et al., 1993) in signaling for
activation. Dystrophic neurites, activated microglia and proinflammatory cytokines are
the inflammatory markers that are found surrounding the Aβ lesions in the human brain.
An array of different aggregate morphologies ranging from dense core neuritic plaques to
granular diffuse wispy Aβ deposits are observed in the human brain. However, only the
plaques seem to provoke the inflammatory response (Selkoe, 2004), and microglia were
observed surrounding only the dense core plaques and not diffuse plaques.

In this study we used THP-1 monocytes to investigate the Aβ-induced
proinflammatory response. These cells have been used extensively in such studies since
they display a similar pattern of activation to that of microglial cells (Klegeris et al.,
1997, Yates et al., 2000, Combs et al., 2001). Aβ solution was allowed to aggregate over
a time period and monitored for the ability to induce a proinflammatory response from
THP-1 monocytes. Earlier studies have used Aβ(1-40) preparations in acidic pH to
monitor the fibrillization of Aβ and also to quantitate the nucleation and elongation rate
constants (Lomakin et al., 1996). The fibrils formed were morphologically identical to
the ones formed in vivo (Lomakin et al., 1996). We observed that an intermediate Aβ(142) species formed in aqueous solutions (pH 3.6-4) was optimal in inducing a

139

proinflammatory response. The peak activity correlated with the formation of short
fibrillar structures that appeared early on in the time course. There was slight shift in the
peak cellular response due to the variation in the Aβ lots but nevertheless the peak was in
the intermediate time points (48-96 hours) during the course of aggregation (Fig 3.1).
The proinflammatory activity diminished with the appearance of fibril structures (216
hour).

Modulation of aggregation of Aβ(1-42) and Aβ(1-40), by increasing the

temperature of the reaction conditions, resulted in the formation of different types of
aggregates (Fig 3.9-11), but they did not provoke a proinflammatory response. Aβ(1-42)
fibrils formed at neutral pH in PBS were also not effective in inducing a proinflammatory
response (Fig 3.13). In fact, the aggregation at neutral pH, and increased ionic strength
promotes aggregation as shown in the TEM images and ThT fluorescence data (Fig 3.133.14). The data indicates that acceleration in the aggregation process may have bypassed the formation of the transient fibrillar structures that induces the maximum
proinflammatory response. The OC-immunodepletion studies suggest that the active
Aβ(1-42) aggregation species is reminiscent of fibrillar oligomers previously reported
(Kayed et al., 2007). There is evidence for the formation of Aβ in acidic conditions. The
build up of intracellular Aβ may be an early event in the pathogenesis of AD and Downs
Syndrome (LaFerla et al., 2007). Accumulation of intracellular Aβ precedes formation of
extracellular deposits (Mori et al., 2002). AD and Downs syndrome brains were analyzed
along with the control brains and the data indicates that most of the intracellular Aβ ends
at residue 42 (Takahashi et al., 2002). Further, it is suggested that endosomes are the
likely sites of Aβ generation due to their acidic nature, and the enzymes BACE-1 and βsecretase have optimal activity at the acidic pH. There is also evidence showing the
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interaction of BACE-1 and APP by FRET (Kinoshita et al., 2003). The link between
extracellular and intracellular Aβ is still under investigation. However, immunotherapy
studies show that removal of extracellular plaques are slowly followed by the removal of
intracellular plaques (Oddo et al., 2004). These findings suggest that extracellular Aβ
may be formed from the intraneuronal pools and there exists a dynamic equilibrium
between the pools, such that when the extracellular pools are removed the intraneuronal
pools are forced out of the cell. At present not much is known about the morphology of
the intraneuronal Aβ. We have seen that Aβ(1-42) in aqueous solution (pH 3.6-4) form
short fibrillar structures that are capable of inducing proinflammatory response (Fig 3.2).
It is possible that these fibrillar precursors may form intraneuronally and when secreted
lead to the activation of the microglial cells that in turn induces the proinflammatory
response. Freshly reconstituted Aβ solutions have punctuate species <2 nm, and DLS
measurements of freshly reconstituted Aβ showed a predominant peak of 1nm species
that corresponds to monomer.

AFM image analyses have shown that the

proinflamamtory species have a mean height and standard deviation (SD) of 4.2 +/- 1.4
nm respectively. AFM imaging of Aβ aggregation species over time was helpful in
providing information regarding the dimensions and morphology of the aggregated Aβ.

Modulation of aggregation conditions like change in pH, temperature and mode of
aggregation (quiescent/agitation) have indicated a change in the fibril structure and
neuronal toxicity. Solid state structural studies indicate the presence of in registerparallel β-sheets for full length Aβ(1-40), Aβ(1-42) and shorter fragment Aβ-(10-35)
(Benzinger et al., 2000, Tycko, 2003). Our studies show that changing the pH and ionic
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strength of aggregation solutions altered the fibril morphology and diminished the
proinflammatory response (Fig 3.13). Aβ(1-40) and the shorter peptide Aβ-25-35 failed
to stimulate the THP-1 monocytes for a proinflammatory response under similar
aggregation conditions. This may perhaps be due to the slow nucleation propensity of
Aβ(1-40) thereby resulting in the formation of a very low concentration of fibrillar
oligomers. Aβ-25-35 is supposed to aggregate fast and the biological activity can be
compared to that of Aβ(1-42), but in our studies this shorter peptide failed to stimulate
the proinflammatory response. It is possible that the last two amino acids in Aβ(1-42) are
very important for the formation of the active proinflammatory species.

The intermediate fibrillar species in Aβ(1-42) aqueous solution was the most active
in inducing a proinflammatory response. We tried to further characterize the aggregation
species by separating out fibrils from solution by ultracentrifugation (100,000 x g and
150,000 x g). Our results indicate that fibrillar structures are soluble and centrifugation
supernatants are able to stimulate the cells for TNFα production (Fig 3.16-17). AFM
image analysis showed a decrease in fibrils in the supernatant. But this decrease did not
cause a drastic change in the proinflammatory signal.

In order to characterize the

aggregation species further, we used conformation-specific antibodies.

These

conformation-specific antibodies have the ability to distinguish between fibrillar and
oligomeric species (Kayed et al., 2007). OC antisera can bind fibrillar species and
precursors to fibrils that have already formed a fibrillar core structure. In fact, (Kayed et
al., 2007) reported the existence of prefibrillar oligomers that were found to be different
from fibrillar oligomers. Since the OC sera can detect any fibrillar species, we chose the
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time point of aggregation that gave the maximum proinflamamtory activity to conduct
immunodepletion studies.

The data indicate that the selective removal of fibrillar

oligomers from the aggregation solution resulted in lowering the proinflammatory signal
(Fig 3.20).

AFM imaging of the SEC fraction that eilicited the maximum

proinflammatory response showed the presence of short rod like fibrillar structures (Fig
3.21D). These findings substantiate our hypothesis that small units of the intermediate
fibrillar precursors are optimal for inducing proinflammatory response. The small units
are crucial since we have observed that continued aggregation, and accelerated
aggregation resulted in fibrils that failed to stimulate the cells.

These active

proinflammatory species seem to be transient and appear simultaneously with the fibrils.
From the time course of aggregation it is evident that these transient small units disappear
to form bigger units mostly due to elongation. The intermediate species bound well to
OC sera indicating presence of fibrillar species. These fibrillar oligomers may be similar
to “seed” aggregates in which the peptide is organized in the same lattice structure as that
of the fibrils (Glabe, 2008). Further investigations will help decipher if these fibrillar
oligomers are precursors to protofibrils.
Soluble Aβ(1-42) oligomeric species have been implicated as primary toxic species
in many neurodegenerative diseases. In fact, large fibrillar plaques provide much less Aβ
surface area to neuronal membranes compared to a number of small oligomers. It is
possible that a group of small oligomers can diffuse into synaptic clefts and these
assemblies are better candidates for inducing synaptic dysfunction (Haass and Selkoe,
2007). Amongst the several unresolved questions, one question raised is the possible role
of soluble oligomers in triggering a proinflammatory cascade. It is possible that these
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species could activate the local microglia and astrocytes either directly or indirectly that
could lead to synaptic dysfunction (Haass and Selkoe, 2007). Our findings indicate that
the soluble prefibrillar oligomeric species formed during the intermediate stage of the
aggregation pathway are optimal for inducing a proinflammatory response. This could be
the partial answer to the question raised above, although a thorough characterization of
the proinflammatory aggregation species will answer the question completely.

The

plaque core contains fibrillar Aβ, and there are reports that indicate plaques to be a
reservoir of bioactive molecules (Meyer-Luehmann et al., 2008). These studies also
discuss about the presence of soluble oligomeric Aβ around the plaques. These
oligomeric Aβ contribute to synapse loss in a mouse model of AD (Koffie et al., 2009).
Their studies indicate presence of polymorphic Aβ species not only in the brain
parenchyma, but also within the plaque area. According to our findings, the soluble prefibrillar Aβ(1-42) species are optimal for triggering a proinflammatory response in
human THP-1 monocytes.

These studies provide additional information into the

complexities of Aβ aggregation morphology and may help in deciphering treatment
strategies.

Identification of the favorable conformation of Aβ(1-42) that triggers a

proinflammatory response opens up avenues to further probe into the interaction of Aβ
with cell surface receptors.
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CHAPTER 4

DIVERSE Aβ AGGREGATION ASSEMBLIES AND THEIR ROLE IN ACTIVATION
OF DIFFERENT BIOCHEMICAL PATHWAYS

4.1 Introduction
The neuropathological features of AD include amyloid deposits, neurofibrillary
tangles and selective neuronal loss (Selkoe, 1991). Amyloid deposits contain Aβ, a 4042 residue peptide produced by the endoproteolytic cleavage of amyloid precursor
protein (APP) (Selkoe, 1993). Microglia are the immune cells of the brain. Aβ deposits
attract the microglia and activate them to produce inflammatory mediators, some of
which will act as a feed back to induce further chemotaxis and activation. Once at the
site of Aβ deposition, the activated microglia attempt to phagocytose and clear the
substance, thereby leading to more activation (Rogers and Lue, 2001). The plaques in
AD brain are surrounded by activated microglial cells (Heneka and O'Banion, 2007).
Microglia may be responsible for the phagocytosis and removal of Aβ under normal
conditions (Wisniewski et al., 1991). In AD, it is argued that the microglia clustered
around Aβ deposits become dysfunctional and incapable of removing Aβ (Rogers et al.,
2002).
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The limbic and association cortices of AD brain are surrounded by dead or dying
neurons, activated microglial cells and reactive astrocytes (Selkoe, 1989, Mrak and
Griffinbc, 2001). Aβ induced neurotoxicity has been demonstrated in numerous cell
culture studies (Pike et al., 1993, Lorenzo and Yankner, 1994, Simmons et al., 1994).
Transgenic mice expressing mutant human APP develop neuropathological lesions
similar to those found in AD patients.

Immunization of these mice with Aβ(1-42)

aggregates reverses the neuropathology significantly (Janus et al., 2000, Morgan et al.,
2000). This effect could be due to two possibilities. One is that the antibodies generated
by the host will neutralize Aβ in a restricted compartment, or it may deplete some soluble
form of Aβ. The other possibility could be that the microglia get activated due to the
immunization and this clears the deposited Aβ. These lead to reversal of cognitive
imbalance (Janus et al., 2000, Morgan et al., 2000). The proposed hypothesis is that the
immune system acts as a peripheral sink, traps Aβ, and depletes it from CNS (Matsuoka
et al., 2003, Heneka and O'Banion, 2007). When there is an overwhelming production of
Aβ(1-42), the levels exceed the rate at which the macrophage machinery clears the
amyloid deposits resulting in the plaque core found within the AD brain. Also, the
clearance mechanisms become less efficient as one ages and this causes severe deposition
of Aβ aggregates.

These data indicate the significant contribution of Aβ(1-42) to

neurotoxicity in AD.

Extensive biophysical studies reveal that full length and fragments of Aβ peptides
form intermolecular parallel β-sheet structures in amyloid fibrils (Serpell, 2000,
Antzutkin et al., 2002, Balbach et al., 2002). In addition to β-sheets, turn structures or
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bend structures were also present at positions 24-27 in Aβ(1-40) aggregates (Whittemore
et al., 2005), and positions 26-27 in Aβ(1-42) aggregates (Olofsson et al., 2006).
However, the precise positions of these turn or bend structures in Aβ aggregates are still
under investigation.

The relationship between the turn position and its impact on

inflammatory response is not known.

A detailed investigation into Aβ aggregation

profile may provide clues into the structure-function relationship.
We investigated the relationship between Aβ aggregation state and its role in the
activation of monocytes and their maturation into macrophages. We identified that a
rapidly formed oligomeric aggregation species is responsible for the maturation of
monocytes

into

macrophages,

and

an

intermediate

fibrillar

oligomer

elicits

proinflammatory response via TLR2 and TLR4 receptors.

4.2 Role of Aβ Aggregation State in Monocyte Recruitment

This study was done in collaboration with Nikkilina Crouse, and the work is
published in (Crouse et al., 2009). The cell surface represents the first site of interaction
between extracellular Aβ and neurons. Therefore the cell surface may be the location
where the neurotoxic cascade is initiated (Bateman et al., 2007). Neurotoxicity studies of
Aβ indicate that aggregated Aβ is generally more toxic than monomeric Aβ (Pike et al.,
1993, Simmons et al., 1994, Podlisny et al., 1998, Walsh et al., 1999, Walsh et al., 2002).
Blood monocytes represent a large pool of scavenger and potential effector cells
inside blood vessels both in homeostasis, as well as, during inflammatory processes
(Auffray et al., 2007). In mammals, monocytes also represent the accessory cells that
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link inflammation and innate defense against microorganisms to adaptive immune
responses (Auffray et al., 2009). Aβ is believed to play roles in monocyte migration (Yan
et al., 1996, Giri et al., 2000, Le et al., 2001), adhesion and differentiation into
macrophages (Yan et al., 1996). Aβ assemblies exhibit a wide range of morphologies
that appear to stimulate different types of biologic responses in vivo.

The type of

aggregation species or the receptor mechanisms that causes the monocyte/microglia
recruitment, monocyte differentiation, and microglial activation are not fully understood.
We investigated the ability of Aβ aggregation species to induce monocyte maturation into
an adherent form.

4.3. Aβ(1-42) Induces THP-1 Monocyte Adhesion and Maturation

THP-1 monocytes cell model system was used for studying the monocyte
recruitment and differentiation process since they are non-adherent and have a round
morphology (Tsuchiya et al., 1980). They normally circulate in the blood. In the event
of a proinflammatory, or immune stimuli in the periphery, the monocytes are recruited to
the site and are differentiated into macrophages. The differentiation process is an attempt
to round up and destroy the foreign pathogen, and prevent further damage to the body.
THP-1 monocytes can be induced to differentiate along the monocytic pathway. These
cells can be converted into mature cells with functions of macrophages by treatment with
phorbol diesters (Tsuchiya et al., 1982).

Phorbol-12-myristate-13-acetate (PMA) is

known to induce cell differentiation. (Schwende et al., 1996) have reported that PMA
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Fig 4.1 Aβ(1-42) induces monocyte adherence comparable to PMA. THP-1
monocytes were treated with 10 ng/ml PMA or 15 µM Aβ(1-42) from a freshly
reconstituted 100 μM water solution and incubated for 6 hours at 37°C. Percent
adherence was determined by direct cell counting as described in the methods. Standard
error bars were calculated from n=17 trials for PMA and n=22 trials for Aβ(1-42). Water
(n=15) controls induced 5 ± 1% adherence. Courtesy Nikkilina Crouse
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induces adherence, and their reports also show a decrease in cell proliferation when
treated with PMA. We used PMA as a control to monitor the differentiation in cells.
When THP-1 cells were incubated with PMA for 6, 24 and 48 hours respectively,there
was monocyte differentiation. The ability to differentiate the monocytes was evaluated
by measuring monocyte adhesion, a marker for cell maturation. Freshly reconstituted
Aβ(1-42) in water (100 µM) induced 41.85 +/- 4.14 % adherence, and it was comparable
to the 43.11+/- 3.65 % induction by PMA (10 ng/ml) (Fig. 4.1). The monocyte adhesion
ability was dependent on the concentration of Aβ. When cells were treated with different
Aβ(1-42) concentrations (5, 10, 15 µM), the 15 µM Aβ(1-42) induced maximum
adherence. (data not shown). We used this concentration for further experiments.

4.4 Freshly solubilized Aβ(1-42) Induces Maximum Monocyte Maturation Compared to
Aggregated Aβ(1-42).
The influence of Aβ(1-42) aggregated state in inducing the monocyte maturation
was tested by incubating Aβ(1-42) for longer incubation time.

Aβ(1-42) was

reconstituted in water, an aliquot was treated with the cells immediately, and the
remaining solution was allowed to aggregate at 4C.

At specific time points of

aggregation (0, 48, 72, 96, 120, 144, 216 hours), aliquots of Aβ(1-42) aggregation
solution were treated with cells, and the ability to induce the monocyte adhesion was
monitored. The maximum adhesion occurred at zero and 48 hours of aggregation, and
the ability to induce adhesion was lost with increase in the duration of aggregation. AFM
images of samples at the correlating time points showed presence of small globular
species for the freshly reconstituted solution of Aβ(1-42). Small fibrillar structures were
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Fig. 4.2 Aβ(1-42) aggregates in freshly reconstituted solution induce monocyte
adherence. Aβ(1-42)) was reconstituted in sterile water to 100 µM and incubated at 4°C.
(A) At the given times, cells were treated with 15 µM Aβ for 6 hours and adherence was
measured by direct counting as described in the Methods. Error bars represent standard
error for n trials of 19 (0 h), 17 (48 h), 4 (72 h), 5 (96 h), 7 (120 h), 3 (144 h), and 7 (216
h) Courtesy Nikkilina Crouse. (B-E) Representative AFM images of Aβ(1-42)
aggregation at 4°C taken at 0, 48, 96 and 216 hours respectively. Aβ(1-42) was diluted a
concentration of 1 µM and applied on mica grids as described in Methods. Images are 5
µm x 5µm panels.

157

observed after 48 hours along with the small globular species, and by 96 hours, there was
an increase in the number of fibrils, and a significant loss of ability to induce cell
adherence. The data clearly suggest that aggregation species present in the freshly
reconstituted Aβ(1-42) was the most effective in inducing monocyte maturation. Height
analysis of the AFM images showed presence of diffuse material < 1nm in height in the
freshly reconstituted Aβ(1-42). Short rod like structures averaging 4-5 nm appeared by
48 hours and these were able to induce monocyte adhesion but was slightly less than the
zero hour sample. As the aggregation progressed there was an increase in the number of
fibrils. The heights of the fibrils averaged between 5-6 nm. There was significant
increase in the fibril numbers with heights greater than 6 nm after 216 hours aggregation.
We observed the disappearance of the diffuse aggregation species as the aggregation
progressed. The data from this experiment suggests that fibrillar aggregates were unable
to induce maturation of THP-1 monocytes to an adherent form. Several trials of the
experiment showed consistency in this trend although the percent adhesion levels showed
a variation depending on the Aβ(1-42) lot numbers.

4.5 Increase in Peptide Concentration Affects the Ability to Induce Monocyte Maturation

Data from section 4.3 suggests that increased Aβ(1-42) aggregation decreases the
monocyte maturation process. The maximum activity was exhibited by Aβ(1-42) species
present at the time of reconstitution.

We modulated the aggregation conditions by

increasing the starting concentration of the monomer. We hypothesized that, there will
be an increase in the rate of the species that forms immediately after reconstitution. Aβ
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aggregation proceeds by multistep, nucleation-dependent process (Jarrett and Lansbury,
1993). Formation of the nucleation seed is the rate limiting step, so that, in the absence
of preformed seeds, there is a significant lag time for the formation of fibrils. The rate of
monomer incorporation to form fibrils increases as concentrations of monomer and seed
increases (Naiki and Nakakuki, 1996).
We increased the monomer concentration by 10 fold (1 mM) and compared
activity to the 100 µM Aβ(1-42) solution that was used for the experiment in Fig 4.2.
Increased monomer concentration will alter the rate of formation of the early species.
The cells were however treated with the same final concentration of 15µM Aβ(1-42).
The more concentrated 1 mM Aβ(1-42) solution showed a decrease in the ability to
induce monocyte adhesion (Fig 4.3 A). AFM images showed presence of fibers with
heights ranging 2-3 nm immediately upon reconstitution in the 1 mM Aβ(1-42) solution.
Aliquots of the same preparation was analysed by TEM, and the fibril widths were 6-10
nm. Further incubation of 1mM Aβ(1-42) solution for 24 hours resulted in increased
fibril formation compared to Aβ(1-42) 100 µM sample. The fibrils were longer and the
heights were 4-5nm, but the monocyte adhesion inducing activity was diminished (Fig
4.3). The treatment of 1 mM Aβ(1-42) with the cells produced 67 % of monocyte
maturation induced by the 100 µM sample. It is possible that accelerated aggregation
depleted the Aβ species capable of inducing monocyte maturation. The depletion is due
to the rapid aggregation into the fibrillar forms as seen in the AFM images (Fig 4.3 B-C).
These findings suggest that the maturation of monocytes was induced by either a
monomeric, or, oligomeric species that was formed early in the aggregation reaction of
100 µM Aβ(1-42) that was reconstituted in water.

159

A 120

A

% of control adherence

100
80
60
40
20

B0

D

100 µM

Ab(water,1mM)

C

1mM

100 µM

E

1mM

Ab(water,100uM)

Fig 4.3. Increased peptide concentration decreases monocyte adherence. Two
aggregations were set up by reconstituting Aβ(1-42) in sterile water to 100 µM and 1 mM
and incubated at 4°C. A. Cells were treated with 15 µM Aβ for 6 hours and adherence
was measured by direct counting as described in the Methods (Courtesy Nikkilina
Crouse). B-E. Representative AFM images of Aβ(1-42) aggregation. B and D) Aβ(1-42),
100 µM, at zero and 24 hours incubation at 4°C, C and E) Aβ(1-42), 1 mM at zero and 24
hours incubation at 4C respectively. Images are 5 µm x 5µm panels.
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4.6 Monocyte Maturation is Induced by Aβ(1-42) and not Aβ(1-40)
The maximum monocyte adherence was found when THP-1 cells were treated
with freshly reconstituted Aβ(1-42). We hypothesized that the monomeric species may
be potent. Studies of the kinetics of Aβ fibril formation have shown that Aβ(1-42) forms
fibrils significantly faster than Aβ(1-40) (Jarrett et al., 1993). The initial oligomerization
and assembly of Aβ(1-40) and Aβ(1-42) indicate that these peptides have distinct
behaviors at the earlier stages in the assembly, monomer oligomerization (Bitan et al.,
2003). The shorter peptide, Aβ(1-40), is believed to remain in the monomer state for a
longer time than Aβ(1-42) (Walsh et al., 1997). In order to further clarify the Aβ
aggregation species responsible for monocyte maturation, we compared the reactions
between Aβ(1-40) and Aβ(1-42). We tested the ability of Aβ(1-40) to induce monocyte
maturation. Since the aggregation propensity of Aβ(1-40) is much slower we reasoned
that the monomer would remain the solution longer, and we could test our hypothesis to
see if monomer species, or, early oligomeric species was actually inducing the maturation
of monocytes. We investigated the time-dependent aggregation of Aβ(1-40) (100 µM)
reconstituted in sterile water and incubated at three temperatures 4C, 25C, 37C. The
activity was compared to Aβ(1-42) (100 µM) incubated at 4C. Significant difference
was observed in the two peptide solutions immediately after reconstitution. Aβ(1-42)
(100 µM) was able to induce 57% monocyte adhesion while Aβ(1-40) under similar
conditions did not (Fig 4.4 A). Accelerating the Aβ(1-40) kinetics by increasing the
temperature did not induce any monocyte adherence. Continued aggregation of Aβ(1-40)
showed fibrils formation by 216 hours, but none of the intermediates formed had
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Fig.4.4 Aβ(1-40) aggregated at different temperatures does not induce THP-1
adherence. Aβ(1-40) was reconstituted in sterile water to 100 µM and incubated at 4C,
25 or 37°C. Panel A. At the given times, cells were treated with 15 µM Aβ(1-40) for 6
hours and adherence was measured by direct counting as described in the Methods. Aβ(142) incubated at 4C was used as the control, Panel A (circles). Error bars represent
standard error for n trials of 3. Courtesy Nikkilina Crouse. B-D. Representative AFM
images of Aβ(1-40) aggregation taken at 0 hours at the three different temperatures. E-G.
AFM images of Aβ(1-40) aggregation taken at 216 hours at 4, 25 or 37°C, respectively.
Images are 5 µm x 5 µm. The images are in the height mode.
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the ability to induce monocyte maturation. The results suggest that adhesion-inducing
activity was mediated by an aggregation species that was formed in the Aβ(1-42)
pathway, but was not formed by any of the aggregation species formed by Aβ(1-40).
These data led us to hypothesize that the two extra amino acids in Aβ(1-42) may be
important in the formation of species responsible for monocyte maturation process.

4.7 Oligomeric Aβ(1-42) Induces Monocyte Maturation

From the results discussed above, we hypothesized that monomer could still be
the active species, but the activity was dependent on the two additional amino acids in
Aβ(1-42). The extra two amino acids may be crucial for the monomer induced monocyte
adhesion. We have seen in Section 4.5 that the lag phase in nucleation–dependent
polymerization process can be altered by a change in concentration of monomer. Two
Aβ(1-42) aggregation solutions were initiated, one at 50 µM concentration and the other
at a concentration of 100 µM. We were of the opinion that in the 50 µM aggregation
solution the available starting monomer concentration is low and therefore the
aggregation reaction will be slower. Also, there would be availability of high monomer
compared to oligomers due to slower aggregation. On the other hand the 100 µM Aβ(142) solution has more concentration of the monomer thereby driving the reaction towards
oligomer formation. We assumed that this would result in a decrease in the monomer
compared to oligomer. The cells were treated with the same final concentration of 15µM
Aβ(1-42). Cells treated with freshly reconstituted 100 µM Aβ(1-42) induced 58+/- 4%
adhesion while there was only 16+/- adhesion for the cells treated with 50 µM Aβ(1-42)
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(Fig 4.5 A). If monomer was responsible for inducing adhesion then the 50 µM Aβ(1-42)
aggregation solution with a high monomer:oligomer ratio should have induced a high
monocyte adhesion property.

Upon additional incubation for 24 hours the activity

reduced in both aggregation reactions to 41+/- 5 and 12+/-3% adhesion for 100 µM and
50 µM Aβ(1-42) respectively. There was further decrease in the adhesion levels as the
aggregation progressed to 48 hours. AFM images of the freshly reconstituted solutions of
50 µM and 100 µM solutions did not show any distinct morphological species that could
differentiate between the two preparations (Fig 4.5 B). However, the 48 hour images
showed a difference in the extent of aggregation (Fig 4.5 C and D). The images showed
the formation of fibrillar species in the 100 µM preparation that correlated with a drop in
the cell adhesion.

The 50 µM sample at the same time did not have any fibrillar

aggregates, but was not able to stimulate cell adhesion. Though AFM images could not
provide additional information regarding the morphology of the species that induces
adherence in the cells, it was evident that the monomer was not involved in inducing
adherence in the THP-1 cells.

4.8 Mutated Aβ(1-42) (L34P) Does not Induce Monocyte Maturation
The data so far indicated that an active Aβ(1-42) aggregation species was capable of
inducing cell adherence. These active species were formed in freshly reconstituted
solutions of Aβ(1-42) indicating that the species is formed early in the aggregation, and
the role of monomer in the maturation process was ruled out at this point. We wanted to
try a mutational approach to get further clarification of the species that was active in the
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Fig 4.5 Lowering the initial Aβ(1-42) concentration decreases monocyte adherence.
Aβ(1-42) was reconstituted in sterile water to either 100 µM or 50 µM and aggregated at
4°C. (Panel A) At the times indicated, THP-1 cells were treated with 15 µM of either
solution for 6 hours at 37°C. The percent adherence was determined as described in the
Methods. SE was determined for n trials of 3 (0 hours) and 2 (24 hours and 48 hours, 50
µM). Only 1 trial was done for 100 µM at 48 hours. Water-induced adherence controls
(2.8 ± 0.4 %) were subtracted from final percent adherence presented. Differences
between 100 µM and 50 µM treatments were significant at 0 (* p<0.0005) and 24 hours
(** p<0.005) of aggregation. Courtesy Nikkilina Crouse. (Panel B-D) Representative
AFM images of the same experiment B) 50 µM sample after 24 h, D) 100 µM sample
after 24 hours.
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maturation of monocytes. Single mutations in proteins can cause aggregation to switch
from one pathway to the other. Systematic replacement with proline in peptides is a
reliable method for predicting the secondary structure (Wood et al., 1995). Proline
residues are rarely present in the β- sheets, but can easily be accommodated in the turns
and bends (Chou and Fasman, 1978, Lifson and Sander, 1979). Hence, proline residues
can be introduced into peptides to slow down the aggregation process. Liu et al., (2004)
investigated the aggregation of Aβ using different Aβ fragments and concluded that
residues 17-20 and 30-35 are the important regions for aggregation. Introduction of
proline into Aβ peptide sequence can improve the solubility and also block or reduce
aggregation (Wood et al., 1995) We tried a mutated Aβ(1-42) L34P peptide for further
probing. If the last two amino acids in Aβ(1-42) were responsible for transformation of
monocytes into macrophages, the Aβ(1-42) L34P should also be able to form the active
species. The leucine to proline mutation at residue 34 slows down aggregation and
destabilizes the fibrils (Williams et al., 2004). This mutation enables the peptide to
remain in the non fibrillar form for a longer time. However, Aβ(1-42) L34P prepared
under similar conditions failed to induce monocyte adhesion after reconstitution in sterile
water. The cells responded to differentiation by PMA in these experiments (data not
shown). Even prolonged incubation up to 168 hours failed to induce monocyte adhesion.
Aβ(1-42) L34P did not produce any fibrillar structures as seen in the AFM images.
These data suggest that a rapidly forming Aβ(1-42) oligomeric species was active in
inducing monocyte cell adhesion. These results clearly indicated the monomer was not
involved in inducing differentiation in monocytes.
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Fig. 4.6 Aβ(1-42) L34P does not induce THP-1 monocyte adherence
Aβ(1-42) (L34P) was reconstituted in sterile water to 100 µM and incubated at 4°C. A.
At the given times, cells were treated with 15 µM Aβ L34P (triangles) for 6 hours and
adherence was measured by direct counting as described in the Methods. Error bars
represent standard error for n trials of 5 for Aβ(1-42) L34P. The time course for Aβ(1-42)
(circles) from Fig 4.2 is shown for comparison. Courtesy Nikkilina Crouse. B-C.
Representative AFM images of Aβ(1-42) L34P aggregation at 4°C taken at 0 (B) and 168
hours (C), respectively. Images are 5 µm x 5 µm and taken as described in Methods.
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However, there was rapid aggregation when Aβ(1-42) (L34P) was reconstituted in water
and incubated at 37C. The measured pH of Aβ(1-42) (L34P) solution was 3.4. This pH
was close to the measured pH of Aβ(1-42) solutions reconstituted in water. Dense fibrils
formed upon incubation at 37C for 24 hours. The fibril density increased as the
aggregation progressed (Fig 4.7). We also noticed less diffuse structures at the start of
the aggregation reaction (Fig 4.7 A). Upon prolonged incubation at 37C, fibrils were
sheared (Fig 4.7 F-G). It is clear that these morphologies failed to induce maturation in
THP-1 monocytes. However, the ability of these aggregates to induce a proinflammatory
response is yet to be probed. Aβ(1-42) (17-35) fragment contained a high ratio of β-sheet
structure, and was comparable to full length Aβ(1-42) (45% and 41%) (Liao et al., 2007).
The mutation at position 34 may alter the β-sheet structure and may have a different
effect on the proinflammatory-stimulating activity.

These findings may provide

important information towards the correlation of structure and biological activity.

4.9 Amyloid Derived Diffusible Ligands (ADDLs) Not Effective Inducers of
Monocyte Adhesion

We wanted to investigate the effect of oligomers on monocyte maturation process.
Lambert et al., (1998), reported the detection of small globular structures ~ 5-6 nm in
diameter which they referred to as ADDLs.

These structures were free of large

protofibrils or fibrils (Walsh et al., 1997, Harper et al., 1999). Also, Aβ(1-42) appear to
populate these structures to a higher degree than Aβ(1-40) (Walsh et al., 1997, Stine et
al., 2003). ADDLs cause neuronal cell death, block LTP (Lambert et al., 1998) and
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Fig 4.7. Aβ(1-42) (L34P) aggregates rapidly at high temperatures. Aβ(1-42)(L34P)
was reconstituted to 100 µM in water and allowed to aggregate at 37C. At specific time
points an aliquot was removed, diluted to 1µM and grids were prepared for AFM imaging
as described in Methods. A-G. AFM images at zero (A), 24 hours (B), 48 hours (C), 72
hours (D), 96 hours (E), 168 hours (F), and 216 hours (G). The image panels are 5µm x
5µm and are in the “height” mode
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inhibit reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
in neural cell lines, which is an indication of cell death (Dahlgren et al., 2002, Wang et
al., 2002, Kim et al., 2003) When low concentrations of ADDLs (5 nM) were incubated
with organo typic mouse brain culture slices for 24 hours there was a 20 % loss in cell
number. However, at higher concentrations (500 nM), and incubation for shorter periods
resulted in complete loss of LTP (Lambert et al., 1998, Wang et al., 2002). Since our
data indicates that Aβ(1-42) oligomeric species was causing monocyte adhesion, we
wanted to see if ADDLs had any effect on THP-1 monocyte adhesion. The preparation
of ADDLs was different from the regular Aβ(1-42) aggregation reactions. The protocol
includes an incubation step for 24 hours, and the centrifugation supernatant after 24 hours
was called ADDLs. For our experiments, we tested the pre-centrifugation solution (total)
and the ADDLs. The pre-centrifugation solution induced 6+/-3% and ADDLs induced 7
+/- 2% adhesion respectively (Fig 4.8 A).
AFM images showed the presence of small oligomeric species ranging from 1-6
nm ( mean = 3.0 +/- 1.3 nm SD) respectively (Fig 4.8 C). The morphological aspects of
the spherical aggregates correlated with earlier reports of ADDLs (Dahlgren et al., 2002).
However, the cellular data suggest that Aβ(1-42) oligomeric species that induces cell
adhesion was different from ADDLs. Moreover, ADDLs are prepared in a different
solution, and we have seen in Chapter 3 that change in solution conditions alter the
aggregation morphology, and biologic activity. It is possible that the active Aβ(1-42)
species are different and are generated before the ADDLs-like conformation is formed.
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Fig 4.8 ADDLs failed to induce monocyte adherence. ADDLs were prepared in
DMSO/ice cold Ham‟s F12 medium with phenol red as described in Methods. Panel A
Cells were treated with the Aβ(1-42) aggregation solution prior to centrifugation (Total)
or ADDLs at a final concentration of 15 µM Aβ(1-42). PMA (10 ng/ml was included as
control. Adherence is presented as the average ± SE for n=2 trials for PMA and n=4 trials
for Total and ADDLs over two separate experiments. Courtesy Nikkilina Crouse,
University of Missouri, St Louis. Panel B-C. AFM images of Total (Panel B), and
ADDLs preparation (Panel C) that were used to treat THP-1 cells. The images are 5 µm x
5 µm panels and are shown in the “height” mode.
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4.10 Intermediate fibrillar Aβ(1-42) Aggregation Species Activate Innate Immune
Response in THP-1 Cells via Toll-like Receptors (TLRs) 2 and 4

This work was done in collaboration with Maria Udan and is published in (Udan
et al., 2008). TLRs are known to comprise a family of 10 proteins (Akira, 2003). TLRs
are often considered to be the staring point of immunity. They function in continuous
sampling of extracellular environment, and informing the cell to respond to infection.
These cellular responses are facilitated via signaling pathways (Parker et al., 2007). One
of the earliest phagocytes to respond to infection is the tissue macrophage.
originate as monocytes in the peripheral blood system.

These

TLR stimulation activates

numerous genes in the human monocytes, leading to the release of cytokines, chemokines
and growth factors that exert potent autocrine and paracrine inflammatory responses.
(Kopydlowski et al., 1999, Wang et al., 2000, Ritter et al., 2005).
Human THP-1 monocytes produce significant proinflammatory response when
treated with aggregated Aβ (Klegeris et al., 1997, Yates et al., 2000). Aβ(1-42) peptides
were prepared by reconstitution in water and incubated at 4C as described in Methods,
and the aggregation was monitored by AFM. The freshly reconstituted Aβ(1-42) solution
showed a dense population of punctuate species that had very little stimulatory effect on
the cells for a proinflammatory response. Continued aggregation produced thin flexible
fiber like structures. Over the time course of aggregation, we identified that the fibers
formed at 48 hours was able to induce maximum proinflammatory response. AFM height
analysis indicated the presence of fibrils that fell into two populations. One was the most
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populated peak that had a mean height of 4.4 nm +/- 0.1 nm and the other was a
population of fibers that had a mean height of 7.9 +/- 0.6 nm respectively. Prolonged
incubation beyond 96 hours incubation at 4C resulted in the loss of cell stimulation.
From Chapter 3 we have seen that fibrillar oligomers were optimal to stimulate maximum
response. The objective of the study was to determine which transmembrane TLR plays
a functional role in transducing the Aβ-induced innate immune signal through the
membrane.
A TLR neutralization assay was developed to probe the TLRs that mediate the
Aβ(1-42) induced proinflammatory response. The assay was initially tested on the TLR
agonists LPS and Pam3CSk4 in order to determine the sensitivity of the assay (Udan et al.,
2008) (data not included). Once we determined the sensitivity of the assay, we conducted
the neutralization studies against the Aβ(1-42) proinflammatory response. In Chapter 3,
we have already seen that aggregated Aβ(1-42) that has been incubated at 4C for 48
hours or 72 hours stimulated maximum proinflammatory response. Hence, we used
Aβ(1-42) that has been aggregated for 48-72 hours for the neutralization assays. Both
TLR2 and TLR4 neutralizaton resulted in the attenuation of the Aβ(1-42) induced
proinflammatory signal, with the TLR2 showing a greater degree of blocking activity.
The antibody neutralization experiments indicated that multiple TLRs mediate the Aβinduced activity. When the cells were neutralized by a combination of TLR2 and TLR4
antibodies, there was increased blocking of the Aβ(1-42) induced proinflammatory signal
(Fig 4.9). These data indicate that both TLR2 and TLR4 have active roles in mediating
the Aβ(1-42) induced innate immune response.
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The interaction between Aβ- aggregates, TLRs and innate immunity will provide
some more details into the complexities of the AD etiology. From chapter 3 we have
identified that small intermediate Aβ(1-42) fibrillar oligomers are optimal for inducing
proinflammatory response. We will be extending the studies to get more information
regarding the interaction of Aβ with the cells. We have done preliminary studies to label
the Aβ(1-42) with immunogold label antibodies (Fig 4.10). We will be extending the
investigations to study the interaction between Aβ and the cell membranes using the
immunogold label studies

4.11 Discussion
The role of macrophages in the innate immune system has gained lot of
importance, and it has been established that they are crucial for defense against microbes
and removal of cellular debris (Fiala et al., 2007). Brain amyloidosis is hypothesized as a
very crucial mechanism in the AD brain. Accumulation of Aβ either in fibrillar, soluble
or oligomeric conformations, is toxic to neurons. (Lambert et al., 1998, Hardy and
Selkoe, 2002, Oddo et al., 2006). Neuropahological study of AD and control brains
showed penetration of blood derived monocytes across brain microvessels, excessive
engorgement of macrophages with Aβ. Also, there was retention of these macrophages
in the wall of congophillic vessels (Fiala et al., 2002). Despite data suggesting the
recruitment of non resident cells into the CNS, there is still no clear picture of how the
transformation from monocytes to macrophages occurs. Human monocytes from
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Fig 4.9 TLR2, TLR4 play an active role in Aβ-induced innate immune response
activation. Aβ(1-42) 100 μM was prepared in sterile water and incubated at 4C for 48-72
hours depending on the peptide lot as described in Methods. THP-1 monocytes were preincubated with 10 μg/ml of TLR2, TLR4 CD14(InvivoGen) antibodies, or IgG isotype
controls, as described in Methods. Isotype controls were rat IgG (Sigma) for TLR2 and TLR4
and IgG1 for CD14. After incubation, THP-1 cells were stimulated with 15 μM of Aβ(1-42)
for 6 hours. TNFα was measured using ELISA.Courtesy Maria Udan.
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B

Fig 4.10. Immugold labeling of Aβ(1-42) fibrils. Aggregated Aβ(1-42) (100 µM) was
diluted to concentration of 20 µM and applied on to formvar coated copper grids as
described in Methods. The grids were incubated with Aβ sequence specific antibody Ab
9 for an hour, followed by incubation with secondary antibody conjugated to 10 nm gold
particles. The grids are stained with 2% uranyl acetate and imaged using JOEL TEM
microscope. (Panel A) TEM image with a magnification of 10 k.The scale bar represents
200 nm. (Panel B) TEM image with a magnification of 25 k. Scale bar represents 100
nm.
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different donors were tested for their ability to differentiate into macrophages. These
studies have shown that in the presence of Aβ(1-42), the monocytes differentiate into
macrophages and also have the ability to secrete cytokines and chemokines (Fiala et al.,
1998). The aggregation state of Aβ plays a crucial role in the ability to interact with
cells. Structural polymorphism is a prominent feature in Aβ aggregation. Aβ that is
found in the parenchyma of the brain have been shown to be a continuum of structures,
and is not limited to a specific aggregation species.(Selkoe, 2004). We have identified
that an early oligomeric form of Aβ(1-42) can transform the monocytes into an adherent
form. The adherence induced by this oligomeric Aβ(1-42) is comparable to a known
differentiating agent, PMA (Fig 4.1).

We also observed that the ability to induce

monocyte maturation is lost as Aβ(1-42) aggregates into fibrils. The AFM images
indicate that small globular species were predominant at the time of reconstitution (Fig
4.6 B). As aggregation proceeds, fibrillar structures are formed that led to a decrease in
the ability to convert the monocytes into the adherent form. The shorter peptide Aβ(140) did not induce cell adherence in spite of increasing the aggregation temperature (Fig
4.4). This confirms that the active species was formed in the Aβ(1-42) aggregation
pathway. The mutational study with Aβ(1-42)(L34P) was done since this peptide does
aggregate well due to the presence of proline at residue 34 (Williams et al., 2004). We
hypothesized that there would be high monomer to oligomer ratio due to the reduced
potential to aggregate. AFM images confirmed that the aggregation was not rapid, but
could not specifically identify the specific species (Fig 4.6). Decreasing the amount of
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starting monomer concentration, could increase the possibility of a large monomer to
oligomer ratio. Decreasing the monomer concentration to 50 µM extended the lag phase
of aggregation compared to 100 µM Aβ(1-42) (Fig 4.5). The fact that the 50 µM Aβ(142) preparation induced less cell adherence than the 100 µM sample clearly rules out the
role of monomer in monocyte maturation. Therefore it is clear that specific Aβ(1-42)
oligomeric species stimulates the monocyte adherence. ADDLs are oligomeric species,
yet, were not able to induce monocyte adhesion (Fig 4.8). ADDLs are species that are
formed after 24 hours incubation. The active species in our experiments are formed at
the time of reconstitution of Aβ(1-42) solution. It is possible that the active Aβ(1-42)
oligomeric species are smaller than ADDLs . The data from this part of the study
indicate that Aβ(1-42) is able to induce adherence in the non adherent THP-1 monocytes.
These data may provide further information in understanding the recruitment and
transformation of non-resident monocytes into the CNS in AD.
We have seen that an early oligomeric species induces adherence in monocytes
(Crouse et al., 2009). The data clearly indicates that the Aβ(1-42) aggregation progresses
to form fibrillar structures that diminished the ability to induce cell adhesion, but induces
a proinflammatory response in THP-1 cells. Here we see the influence of Aβ aggregation
state in eliciting a biological response. It is possible that the early oligomeric species
induces the recruitment of monocytes from blood. The activation of microglia may be
separate process from that of monocyte recruitment or differentiation. From our data we
see that as the aggregation progresses into formation of the intermediate fibrillar species
it triggers the proinflammatory response. These fibrillar forms triggers the microglial
activation. Our data also shows that an intermediate fibrillar oligomeric species of Aβ(1-
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42) triggers the proinflammatory response that is mediated via receptors TLR2 and
TLR4 (Udan et al., 2008). We have also seen that neutralization of TLR2 and TR4
results in attenuating the fibrillar oligomeric Aβ(1-42) induced signal (Fig 4.9).
However, blocking the TLR2 and TLR4 did not attenuate the oligomeric Aβ(1-42)
induced monocyte adherence (data not shown).

These data further clarify the

significance of Aβ aggregation state and its involvement in different biochemical
pathways.

These data may provide important clues into the different stages in the

inflammatory pathway.
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CHAPTER 5

Conclusion
Data from our studies indicate that Aβ(1-42) has the ability to stimulate the THP1 monocytes for a proinflammatory response. We have also shown the significance of
the Aβ(1-42) aggregation state in eliciting this response from the cells. By using a
combination of biophysical and cellular assays we have identified that an intermediate
fibrillar species in Aβ(1-42) aggregation pathway is capable of eliciting maximum
proinflammatory response. Our data also indicate that only intermediate species formed
from Aβ(1-42) aggregation solution incubated at 4C could activate the cells for a
response. Aggregation of Aβ(1-40) under similar conditions did not elicit stimulatory
activity.

Furthermore, high speed centrifugation of Aβ(1-42) aggregation solution

established the solubility of the proinflammatory species. The centrifugation supernatant
was active in stimulating the cells. Using conformation-specific antibodies, we were able
to

categorize

the

proinflammatory

species

as

fibrillar

oligomers.

Our

immunoprecipitation (IP) protocol, using fibril-specific antibody (OC immune serum),
depleted the active species from aggregation solution, which was confirmed by depletion
of proinflammatory response by the IP supernatant.

Characterization of Aβ(1-42)

aggregation solution by SEC enabled isolation of the peak fraction that gave maximum
proinflammatory response. These studies strengthen our earlier findings (Udan et al.,
2008) where we had shown the involvement of toll-like receptors, particularly TLR4 and
TLR2, in Aβ-induced response. We have also shown that an early oligomeric species in
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the Aβ(1-42) aggregation pathway has the ability to transform monocytes into an
adherent form that look like macrophage cells. Here again we were able to display the
exclusive property of Aβ(1-42) to form an early oligomeric assembly that was not formed
by the oligomeric Aβ(1-42) ADDLs and the mutated Aβ(1-42) (L34P) (Crouse et al.,
2009). Overall, our data displays the correlation between Aβ and the human immune
response, and also pinpoints the assembly state that is involved in activating the different
stages of inflammatory pathway. This study provides further clues into understanding the
mechanism of Aβ induced inflammatory response and may be useful in designing
therapeutic strategies towards the treatment of AD.
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